<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11691682</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric aspects of impulsivity.</ArticleTitle><Pagination><MedlinePgn>1783-93</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors discuss the relationship of impulsivity to psychiatric disorders and present selected hypotheses regarding the reasons for these relationships.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Previous research has shown significantly higher levels of impulsivity among patients with conduct disorder, personality disorders, substance use disorders, and bipolar disorder, compared to other psychiatric patients or healthy comparison subjects. A literature review of the theoretical bases of the relationship between these disorders and impulsivity is presented. Measurements of impulsivity and treatment options are discussed in relation to the physiology of impulsivity and the disorders in which it is a prominent feature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Impulsivity, as defined on the basis of a biopsychosocial approach, is a key feature of several psychiatric disorders. Behavioral and pharmacological interventions that are effective for treating impulsivity should be incorporated into treatment plans for these disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The high comorbidity of impulsivity and selected psychiatric disorders, including personality disorders, substance use disorders, and bipolar disorder, is in a large part related to the association between impulsivity and the biological substrates of these disorders. Before treatment studies on impulsivity can move forward, measures of impulsivity that capture the core aspects of this behavior need to be refined and tested on the basis of an ideologically neutral model of impulsivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moeller</LastName><ForeName>F G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Houston Health Science Center, 77030, USA. Frederick.G.Moeller@uth.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barratt</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Dougherty</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA-00403</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA-08425</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000987" MajorTopicYN="N">Antisocial Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>118</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11691682</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.158.11.1783</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11353595</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-9338</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences.</ArticleTitle><Pagination><MedlinePgn>167-72</MedlinePgn></Pagination><Abstract><AbstractText>The validity and nosologic status of schizoaffective disorder is still a controversial issue. This study was conducted to analyze the demographic, clinical and prognostic variables that determine the validity of the diagnosis of schizoaffective disorder bipolar type. We analyzed and compared 138 outpatients: 67 with type I bipolar disorder, 34 with schizoaffective disorder bipolar type and 37 with schizophrenia. They were all diagnosed following research diagnostic criteria and assessed according to the Schedule for Affective Disorders and Schizophrenia. Schizoaffective unipolar patients were excluded. The results reaffirmed that, from the standpoints of demographics, clinical features and prognosis, schizoaffective disorders bipolar type can be classified as a phenotypic form at an intermediate point between bipolar I disorder and schizophrenia. These results emphasize the importance of longitudinal follow-up in the diagnosis and assessment of psychotic syndromes. Although cross-sectional symptoms were closer to the schizophrenia spectrum, the course of the illness resembled more that of bipolar patients, resulting in an intermediate outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Institute of Psychiatry and Psychology, Department of Psychiatry, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gastó</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11353595</ArticleId><ArticleId IdType="pii">S0924-9338(01)00559-4</ArticleId><ArticleId IdType="doi">10.1016/s0924-9338(01)00559-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5413275</PMID><DateCompleted><Year>1970</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>1970</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The many faces of mania. Therapeutic trial of lithium carbonate.</ArticleTitle><Pagination><MedlinePgn>262-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipkin</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Dyrud</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>G G</ForeName><Initials>GG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002254">Carbonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002254" MajorTopicYN="N">Carbonates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1970</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1970</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1970</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5413275</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1970.01740270070009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21503565</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2011</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0214-4840</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Adicciones</Title><ISOAbbreviation>Adicciones</ISOAbbreviation></Journal><ArticleTitle>[Smoking in affective psychosis: review about nicotine use in bipolar and schizoaffective disorders].</ArticleTitle><Pagination><MedlinePgn>65-75</MedlinePgn></Pagination><Abstract><AbstractText>Affective psychoses include those disorders with psychotic and affective symptoms described in the DSM-IV-TR. In these pathologies, the prevalence of nicotine dependence is very high. The objective here is to carry out a review of the relation between nicotine use and psychiatric disorders considered as affective psychoses at the epidemiological, clinical, prognostic and treatment levels. We review studies published in the PubMed database that include the keywords smoking, tobacco, nicotine and schizoaffective or bipolar disorder. Comorbidity of bipolar and schizoaffective disorder with nicotine consumption is 66-82.5 % and 67%, respectively. On the basis of this review it can be concluded that smoking results in poorer prognosis and greater clinical seriousness of bipolar and schizoaffective disorders. Use of other substances, psychiatric diagnosis, clinical seriousness and caffeine consumption are risk factors for nicotine use. The most effective treatment approach is pharmacological treatment in combination with psychological interventions. The first-line medication for tobacco detoxification and dishabituation are substitution therapy (transdermal patches, sprays, sublingual tablets, sucking pills or nicotine chewing gums), varenicline and bupropion. The medically indicated treatment for psychotic symptoms is atypical antipsychotics, due to their better tolerability profile and better results in smoking cessation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>López-Ortiz</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Psiquiatría del Hospital Universitario Vall d’Hebrón, Barcelona, Spain. c.lopez@pssjd.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roncero</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Miquel</LastName><ForeName>Laia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Fumar en las psicosis afectivas: revisión sobre el consumo de nicotina en el trastorno bipolar y esquizoafectivo.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Adicciones</MedlineTA><NlmUniqueID>9605506</NlmUniqueID><ISSNLinking>0214-4840</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="Y">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21503565</ArticleId><ArticleId IdType="pii">168</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3965440</PMID><DateCompleted><Year>1985</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>1985</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Use of clonazepam in two cases of acute mania.</ArticleTitle><Pagination><MedlinePgn>29-30</MedlinePgn></Pagination><Abstract><AbstractText>Two cases of mania, one psychotic and one nonpsychotic, were treated with clonazepam, 4 mg p.o. q.i.d. In the nonpsychotic patient, complete alleviation of manic symptomatology was noted with use of clonazepam. The psychotic patient showed a reduction in manic behavior during clonazepam therapy, but without concomitant effect on psychotic features. Implications for the use of this novel psychopharmacologic agent are discussed and a possible mechanism of action is proposed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freinhar</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001570">Benzodiazepinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001570" MajorTopicYN="N">Benzodiazepinones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3965440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7362424</PMID><DateCompleted><Year>1980</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>1980</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium: a brake in the rising cost of mental illness.</ArticleTitle><Pagination><MedlinePgn>385-8</MedlinePgn></Pagination><Abstract><AbstractText>Lithium has been extraordinarily successful in the treatment of manic-depression. To compute the economic impact of that success on the United States, an estimate of the cost of care for manic-depression before lithium was introduced was compared with cost estimates after lithium. Economic gains in production were also calculated. Assumptions and exclusions err on the conservative side so that estimates, if inaccurate, are low. The use of lithium as a treatment for manic-depression has saved +2.88 billion in ten years and resulted in a +1.28 billion gain in production, or a conservative total of over +4 billion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reifman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wyatt</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007182" MajorTopicYN="N">Income</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012114" MajorTopicYN="N">Residential Treatment</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7362424</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1980.01780170027002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25311363</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Calcium-dependent intracellular signal pathways in primary cultured adipocytes and ANK3 gene variation in patients with bipolar disorder and healthy controls.</ArticleTitle><Pagination><MedlinePgn>931-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2014.104</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a chronic psychiatric disorder of public health importance affecting &gt;1% of the Swedish population. Despite progress, patients still suffer from chronic mood switches with potential severe consequences. Thus, early detection, diagnosis and initiation of correct treatment are critical. Cultured adipocytes from 35 patients with BD and 38 healthy controls were analysed using signal pathway reporter assays, that is, protein kinase C (PKC), protein kinase A (PKA), mitogen-activated protein kinases (extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK)), Myc, Wnt and p53. The levels of activated target transcriptional factors were measured in adipocytes before and after stimulation with lithium and escitalopram. Variations were analysed in the loci of 25 different single-nucleotide polymorphisms (SNPs). Activation of intracellular signals in several pathways analysed were significantly higher in patients than in healthy controls upon drug stimulation, especially with escitalopram stimulation of PKC, JNK and Myc, as well as lithium-stimulated PKC, whereas no meaningful difference was observed before stimulation. Univariate analyses of contingency tables for 80 categorical SNP results versus diagnoses showed a significant link with the ANK3 gene (rs10761482; likelihood ratio χ(2)=4.63; P=0.031). In a multivariate ordinal logistic fit for diagnosis, a backward stepwise procedure selected ANK3 as the remaining significant predictor. Comparison of the escitalopram-stimulated PKC activity and the ANK3 genotype showed them to add their share of the diagnostic variance, with no interaction (15% of variance explained, P&lt;0.002). The study is cross-sectional with no longitudinal follow-up. Cohorts are relatively small with no medication-free patients, and there are no 'ill patient' controls. It takes 3 to 4 weeks of culture to expand adipocytes that may change epigenetic profiles but remove the possibility of medication effects. Abnormalities in the reactivity of intracellular signal pathways to stimulation and the ANK3 genotype may be associated with pathogenesis of BD. Algorithms using biological patterns such as pathway reactivity together with structural genetic SNP data may provide opportunities for earlier detection and effective treatment of BD. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Gal</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Södersten</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizlin-Hodzic</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ågren</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funa</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490613">ANK3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017487">Ankyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017667" MajorTopicYN="N">Adipocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017487" MajorTopicYN="N">Ankyrins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>02</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25311363</ArticleId><ArticleId IdType="pii">mp2014104</ArticleId><ArticleId IdType="doi">10.1038/mp.2014.104</ArticleId><ArticleId IdType="pmc">PMC4759096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15023493</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 May 15;19(10):4023-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10234031</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics. 2007 Sep;8(9):1097-100</Citation><ArticleIdList><ArticleId IdType="pubmed">17924823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2004 Oct 15;119(2):257-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15479642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2010 Sep;11(6):763-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20334574</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Dec;122(6):507-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20712826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 May;160:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24709015</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Genet. 2009 Feb;25(2):99-105</Citation><ArticleIdList><ArticleId IdType="pubmed">19144440</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Oct;29(10):1831-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15138445</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Oct 1;46(7):929-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10509176</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2008 Dec;18(6):313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19018238</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Nov 19;8(11):e81072</Citation><ArticleIdList><ArticleId IdType="pubmed">24260534</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Sep 18;43(10):977-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21926972</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2005 Mar;8(1):5-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15500705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 Nov;79(4):849-58</Citation><ArticleIdList><ArticleId IdType="pubmed">11723177</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 1;62(7):711-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17568569</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(2):208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11840314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Oct;11(10):965-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16894394</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Metab. 2009 Jun;10(5):433-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19689241</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1995 Aug;118 ( Pt 4):1027-38</Citation><ArticleIdList><ArticleId IdType="pubmed">7655879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 May;31(3):189-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16699605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jul 21;24(29):6578-89</Citation><ArticleIdList><ArticleId IdType="pubmed">15269270</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Sep 30;199(2):92-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22633012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogenet. 2010 Dec;24(4):182-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20615089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Apr 15;22(8):3251-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11943826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):174-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18715651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Biol Ther. 2002 Nov-Dec;1(6):640-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12642687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 May;14(5):487-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19088739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 1999 Dec;1(2):81-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11252663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):558-69</Citation><ArticleIdList><ArticleId IdType="pubmed">18317468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Sep;76(1-3):249-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12943955</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2013 May 21;3:e261</Citation><ArticleIdList><ArticleId IdType="pubmed">23695236</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:92-109</Citation><ArticleIdList><ArticleId IdType="pubmed">19538689</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Oct 29;306(5697):882-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15514161</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol Paris. 2011 Dec;105(4-6):183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21767641</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2008 Oct;31(10):495-503</Citation><ArticleIdList><ArticleId IdType="pubmed">18774185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2005 Jan 15;14(2):241-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15563509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Jan;47(1):26-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22711881</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Jul 29;122(2):261-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16051150</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2002 Dec;43(7):1173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12504924</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 May 1;56(1):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21296169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Sep;12(9):815-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17440432</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):267-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12657366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2002 Nov;52(5):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">12402257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2011 Jan 15;20(2):387-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21037240</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 1995 Oct;90(10):1349-56</Citation><ArticleIdList><ArticleId IdType="pubmed">8616463</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2010 Sep;44(12):748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20185149</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1995 Jul 28;1242(1):11-28</Citation><ArticleIdList><ArticleId IdType="pubmed">7626652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Apr;158:90-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24655771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2014 Jan;39(1):31-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24016415</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1978;(271):5-27</Citation><ArticleIdList><ArticleId IdType="pubmed">277059</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2009 Winter;15(4):333-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19889130</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2000 Winter;71(4):309-29</Citation><ArticleIdList><ArticleId IdType="pubmed">11025910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Jun 15;22(12):4973-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12077194</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Res. 1996 Dec;18(6):559-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8985958</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Apr;29(4):805-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14735135</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):518-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11018224</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2005 Jul;39(4):355-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16044535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Mar 5;274(10):6039-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10037682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1998 Nov 30;143(5):1295-304</Citation><ArticleIdList><ArticleId IdType="pubmed">9832557</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 2001 Feb;13(1):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11163135</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5099-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15044694</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drug Rev. 2006 Summer;12(2):135-48</Citation><ArticleIdList><ArticleId IdType="pubmed">16958987</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Biochim Biophys Sin (Shanghai). 2011 Oct;43(10):745-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21903638</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Dev Immunol. 2013;2013:267871</Citation><ArticleIdList><ArticleId IdType="pubmed">24348675</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2007;435:61-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17998049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2008 Jan 11;132(1):125-36</Citation><ArticleIdList><ArticleId IdType="pubmed">18191226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Jun 24;465(7301):1075-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20543825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Jul;54(7):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">9236543</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2008 Jan;53(1):26-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18286869</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2011 Jun 24;11:103</Citation><ArticleIdList><ArticleId IdType="pubmed">21702894</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Apr 1;33(7):520-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8513036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Feb;56(2):162-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10025441</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12941458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2008 Sep;40(9):1056-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18711365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2010 Apr 15;20(8):2665-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20227879</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2012 Apr;1823(4):826-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22306004</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1995 May-Jun;36(3):267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">7638314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Dec;13(12):1102-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17938637</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4132450</PMID><DateCompleted><Year>1974</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>7860</Issue><PubDate><Year>1974</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Letter: Primary enuresis and affective illness.</ArticleTitle><Pagination><MedlinePgn>733</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Klotz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004775" MajorTopicYN="N">Enuresis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>4</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>4</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4132450</ArticleId><ArticleId IdType="pii">S0140-6736(74)92936-5</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(74)92936-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22386129</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>197</Volume><Issue>1-2</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>The visual P3a in schizophrenia and bipolar disorder: effects of target and distractor stimuli on the P300.</ArticleTitle><Pagination><MedlinePgn>140-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2011.09.030</ELocationID><Abstract><AbstractText>Amplitude reduction of the P300 event-related potential has long been suggested as a marker for schizophrenia. However, recent research has shown that this reduction in the P300 amplitude is not specific to schizophrenia as it can also be observed in related illnesses such as bipolar disorder. Due to this lack of specificity the P300 elicited using traditional oddball paradigms may be a less valuable endophenotypic marker. The current study employed a cognitively demanding three-stimulus oddball paradigm to elicit the P300 to visual target and distracting stimuli. Patients with schizophrenia showed amplitude reductions of P300 components to targets, distractors and frequent stimuli. The P300 in patients with bipolar disorder was not significantly different from either group. The pattern of results may further the understanding of the nature of the impairment in schizophrenia.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bestelmeyer</LastName><ForeName>Patricia E G</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>School of Psychology, Bangor University, Bangor, Gwynedd, UK. p.bestelmeyer@bangor.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018913" MajorTopicYN="N">Event-Related Potentials, P300</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22386129</ArticleId><ArticleId IdType="pii">S0165-1781(11)00688-3</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2011.09.030</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3832143</PMID><DateCompleted><Year>1986</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>5-6</Issue><PubDate><Year>1985</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Colour associations as predictors of the effectiveness of anti-depressant pharmacotherapy in endogenous depressive patients.</ArticleTitle><Pagination><MedlinePgn>305-9</MedlinePgn></Pagination><Abstract><AbstractText>The authors examined the number of associations given for the 8 Lüscher colours by 20 endogenous depressive patients (11 unipolar and 9 bipolar II) before anti-depressant pharmacotherapy and on the 7th, 14th and 21st day of treatment. The depressive patients gave significantly fewer total responses before treatment than the 15 healthy control persons. While the number of associations obtained from the control persons was unchanged at the end of the 1st week, the depressive patients responding to the treatment (responders, n = 15) furnished significantly more responses on the 7th day than before treatment, although there had been no change in the intervening period in the severity of their depression measured by Hamilton depression scale; their clinical state showed a gradual improvement only from the end of the 2nd week. The number of associations obtained from non-responder depressive patients (n = 5) increased only slightly (not significantly). Our preliminary findings suggest that this method could be used to follow changes in the state of depressive patients and to predict their response to anti-depressant pharmacotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demeter</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rihmer</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Frecska</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001244" MajorTopicYN="Y">Association</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003116" MajorTopicYN="Y">Color</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3832143</ArticleId><ArticleId IdType="doi">10.1159/000284418</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10544983</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>1999</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>John Frederick Joseph Cade: family memories on the occasion of the 50th anniversary of his discovery of the use of lithium in mania. 1949.</ArticleTitle><Pagination><MedlinePgn>615-8 and 4 pages following</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cade</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>The Royal Melbourne Hospital, Parkville, Victoria, Australia. CadeJF@nwhcn.org.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016419">Classical Article</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D019477">Portrait</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>Q</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Cade</LastName><ForeName>J F</ForeName><Initials>JF</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>11</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10544983</ArticleId><ArticleId IdType="doi">10.1080/j.1440-1614.1999.00624.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26655121</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Illness history: Not associated with remission during treatment of major depression in 515 mood disorder patients.</ArticleTitle><Pagination><MedlinePgn>118-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.10.058</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)30333-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is suggestive evidence that prior illness history may have little association with response to long-term treatment in bipolar disorder (BD) or recurrent major depressive disorder (MDD), but relationships of illness-history to treatment-response in acute episodes of depression require further testing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We tested for associations of selected measures of illness history with remission during treatment of an acute index episode of major depression in 515 mood-disorder patients (327 MDD, 188 BD), using bivariate and multivariate methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Remission of depression was more likely with lesser initial symptom-severity and bipolar diagnosis, but not related to years since illness-onset, previous depressions or episodes (based on counts, yearly rates, or %-of months ill), or other indices of illness-severity (hospitalization, co-morbidity, suicide attempt).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Likelihood of response to standard treatments for acute major depressive episodes in MDD or BD appeared to be largely independent of prior illness-history.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States; International Consortium for Psychotic and Mood Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States. Electronic address: rbaldessarini@mclean.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States; International Consortium for Psychotic and Mood Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States; Lucio Bini Mood Disorders Center, Cagliari, Sardinia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visioli</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>International Consortium for Psychotic and Mood Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States; Lucio Bini Mood Disorders Center, Cagliari, Sardinia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez</LastName><ForeName>Gustavo H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>International Consortium for Psychotic and Mood Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States; Department of Neurosciences, Palermo University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Major depressive disorder</Keyword><Keyword MajorTopicYN="N">Morbid history</Keyword><Keyword MajorTopicYN="N">Treatment response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26655121</ArticleId><ArticleId IdType="pii">S0165-0327(15)30333-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.10.058</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">243469</PMID><DateCompleted><Year>1978</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0015-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>11</Issue><PubDate><Year>1977</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie, Psychiatrie, und ihrer Grenzgebiete</Title><ISOAbbreviation>Fortschr Neurol Psychiatr Grenzgeb</ISOAbbreviation></Journal><ArticleTitle>[The time-structure of a manic-depressive psychosis (author's transl)].</ArticleTitle><Pagination><MedlinePgn>596-614</MedlinePgn></Pagination><Abstract><AbstractText>Some ideas about the desynchronisation and the restabilisation of the diurnal time-structure in the mood-and-drive system are the background for some hypotheses about the determination of the course and the theory of mixed states of manic-depressive psychoses. A model given in graphs is compared with empiric material from a typical casus, which could be shown with its prodrom and some weeks of its course. The structure of dimensionality was studied by factor-analysis, the time structure was studied by autocorrelation technique. A development of the chronobiological theory seems to be of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Supprian</LastName><ForeName>U</ForeName><Initials>U</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Verlaufsstudien an einer phasischen Psychose.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr Grenzgeb</MedlineTA><NlmUniqueID>0370726</NlmUniqueID><ISSNLinking>0015-8194</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">243469</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30611064</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>246</Volume><PubDate><Year>2019</Year><Month>03</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion.</ArticleTitle><Pagination><MedlinePgn>659-666</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)30174-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.12.030</ELocationID><Abstract><AbstractText Label="BACKGROUND">Hypersomnia is a common problem amongst individuals with Bipolar Disorder (BD). The objective of this meta-analysis is to estimate the frequency of hypersomnia in individuals with BD, and identify associated factors METHODS: Our search focused on articles documenting the frequency of hypersomnia among individuals with BD indexed in PubMed database and in the Cochrane Library, following the recommendations from the Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) Group. A meta-analysis of proportion was conducted; funnel plot and Egger's test were used for the assessment of publication bias. Subgroups analyses were performed in order to evaluate possible confounders and associated factors.</AbstractText><AbstractText Label="RESULTS">We identified 10 studies, which included 1824 patients with BD. The overall estimate of the proportion of BD cases that reported hypersomnia was 29.9% [95% confidence interval (CI): 25.8 - 34.1%, I<sup>2</sup> = 59.2%; p &lt; .05]. The funnel plot and the Egger's test suggest a low risk of publication bias (p = .527). The polarity of mood state, Bipolar Disorder type, use of medication, age, diagnostic criteria and hypersomnia criteria were not significantly related to hypersomnia.</AbstractText><AbstractText Label="LIMITATIONS">There is a possibility that smaller cross-sectional studies were not included. The high heterogeneity between studies is frequent in meta-analysis of both interventional and observational studies. Hypersomnia was not the primary outcome in some of the included studies.</AbstractText><AbstractText Label="CONCLUSIONS">To our knowledge, this is the first systematic review and meta-analysis of hypersomnia prevalence in patients with BD. Further studies focused on clinical correlates and implications for health outcomes in BD are warranted.</AbstractText><CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grigolon</LastName><ForeName>Ruth B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevizol</LastName><ForeName>Alisson P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, ON, Canada; Temerty Centre for Therapeutic Brain Intervention and Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. Electronic address: alisson.trevizol@camh.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerqueira</LastName><ForeName>Raphael O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brietzke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of São Paulo, SP, Brazil; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Chronobiology</Keyword><Keyword MajorTopicYN="Y">Circadian rhythm</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Hypersomnia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30611064</ArticleId><ArticleId IdType="pii">S0165-0327(18)30174-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2018.12.030</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22911320</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Are atypical antipsychotic drugs the first line treatment for bipolar disorders? For].</ArticleTitle><Pagination><MedlinePgn>1190-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-012-3618-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Campus of Aging and Vitality, Wolfson Research Centre, Newcastle University, Institute of Neuroscience, Academic Psychiatry, Westgate Road, NE4 5PL, Newcastle upon Tyne, United Kingdom. heinz.grunze@newcastle.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Pro.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22911320</ArticleId><ArticleId IdType="doi">10.1007/s00115-012-3618-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2009;10(2):85-116</Citation><ArticleIdList><ArticleId IdType="pubmed">19347775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:10-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19538682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33155273</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers.</ArticleTitle><Pagination><MedlinePgn>61-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13254</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess the employment rate and the related background factors among people with schizophrenia or bipolar disorder.</AbstractText><AbstractText Label="METHODS">We identified all people in Sweden aged 18-64 years diagnosed with schizophrenia or bipolar disorder in nationwide registers in the years 2006-2013. The identified individuals were grouped by main activity or source of income. The association between background factors and employment was analyzed with generalized estimating equations (GEE).</AbstractText><AbstractText Label="RESULTS">Three years before the first psychosis or bipolar disorder diagnosis, 24% of the individuals with schizophrenia and 45% of the individuals with bipolar disorder were employed. However, the employment rate dropped around the time of the first diagnosis. Five years later, 10% of the individuals with schizophrenia and 34% of the individuals with bipolar disorder were employed. The most important factors associated with employment after diagnosis were a high level of education, older age at the first registered diagnosis, no substance use disorder, and a low number of previous hospitalizations. Marriage or cohabiting, higher level of education, and higher age at the first diagnosis were associated with an increased employment rate especially among people with schizophrenia, and substance use was associated with a lower employment rate, especially among people with bipolar disorder. Men with bipolar disorder had a higher employment rate than women.</AbstractText><AbstractText Label="CONCLUSION">The employment rate is low among people with schizophrenia and higher among people with bipolar disorder. The association of background characteristics with employment was mostly in the same direction both in schizophrenia and in bipolar disorder.</AbstractText><CopyrightInformation>© 2020 The Authors. Acta Psychiatrica Scandinavica published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Minna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2149-855X</Identifier><AffiliationInfo><Affiliation>Mental Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taipale</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3281-934X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanskanen</LastName><ForeName>Antti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Impact Assessment Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiihonen</LastName><ForeName>Jari</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitterdorfer-Rutz</LastName><ForeName>Ellenor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007182" MajorTopicYN="N">Income</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">employment</Keyword><Keyword MajorTopicYN="Y">income</Keyword><Keyword MajorTopicYN="Y">pensions</Keyword><Keyword MajorTopicYN="Y">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33155273</ArticleId><ArticleId IdType="doi">10.1111/acps.13254</ArticleId><ArticleId IdType="pmc">PMC7839734</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):179-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23379960</ArticleId></ArticleIdList></Reference><Reference><Citation>Disabil Health J. 2018 Jan;11(1):108-115</Citation><ArticleIdList><ArticleId IdType="pubmed">28476583</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Sep;17(6):670-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26529373</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2018 Jul;197:274-280</Citation><ArticleIdList><ArticleId IdType="pubmed">29274734</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2009;78(5):285-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19602917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Oct;133(3):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21620480</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Sep;167(9):1116-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20478878</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 Mar;42(2):443-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25796051</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2019 Nov;54(11):1343-1351</Citation><ArticleIdList><ArticleId IdType="pubmed">31456027</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2010 Oct;25(6):338-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20435449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):166-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17391359</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2007 Jul;191:30-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17602122</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2017 Jun 1;68(6):603-609</Citation><ArticleIdList><ArticleId IdType="pubmed">28142387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 May;16(3):217-29</Citation><ArticleIdList><ArticleId IdType="pubmed">24219657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Dec;106(2-3):337-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18804345</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2012 Sep 06;12:745</Citation><ArticleIdList><ArticleId IdType="pubmed">22950458</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2000 Dec;102(6):432-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11142432</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2019 Oct;140(4):371-381</Citation><ArticleIdList><ArticleId IdType="pubmed">31254386</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2016 Oct 1;67(10):1131-1138</Citation><ArticleIdList><ArticleId IdType="pubmed">27247173</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Sep;199(3):194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">21881098</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Jul;209(1):14-22</Citation><ArticleIdList><ArticleId IdType="pubmed">27103678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Feb;17(1):76-85</Citation><ArticleIdList><ArticleId IdType="pubmed">25056132</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Epidemiol. 2019 Apr;34(4):423-437</Citation><ArticleIdList><ArticleId IdType="pubmed">30929112</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Oct 21;43(6):1176-1189</Citation><ArticleIdList><ArticleId IdType="pubmed">29045744</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2016 Apr;77(4):e429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">27035073</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Psychol. 2016 Nov 18;12(4):659-678</Citation><ArticleIdList><ArticleId IdType="pubmed">27872673</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49</Citation><ArticleIdList><ArticleId IdType="pubmed">15133589</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2020 Mar 1;71(3):250-255</Citation><ArticleIdList><ArticleId IdType="pubmed">31722646</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2013 Jun;48(6):863-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23064396</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2012 Sep;47(9):1381-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22083390</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2019 Oct;13(5):1083-1089</Citation><ArticleIdList><ArticleId IdType="pubmed">30125468</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2011 Jun 09;11:450</Citation><ArticleIdList><ArticleId IdType="pubmed">21658213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Sep 29;370(9593):1146-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17905167</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Ment Health Syst. 2016 Oct 12;10:68</Citation><ArticleIdList><ArticleId IdType="pubmed">27752282</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 Mar;42(2):476-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26433216</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2018 Jul;197:150-155</Citation><ArticleIdList><ArticleId IdType="pubmed">29472164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Feb 20;145(2):156-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22877965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15952962</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>7 Suppl 3</Volume><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>CANMAT guidelines for bipolar disorder: a commentary from South America.</ArticleTitle><Pagination><MedlinePgn>87-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Department of Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. kapcz@terra.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentil</LastName><ForeName>Valentim</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bipolar Disord. 2005;7 Suppl 3:5-69</RefSource><PMID Version="1">15952957</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017408" MajorTopicYN="Y">Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013020" MajorTopicYN="N" Type="Geographic">South America</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15952962</ArticleId><ArticleId IdType="pii">BDI224</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2005.00224.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6137250</PMID><DateCompleted><Year>1983</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>1983</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A risk factor strategy for investigating affective illness.</ArticleTitle><Pagination><MedlinePgn>903-9</MedlinePgn></Pagination><Abstract><AbstractText>A "risk factor" approach to affective illness is outlined. Characteristics which are correlated with vulnerability to depression (or mania) should be sought and attempts made to either modify them or elucidate a pathophysiologic link between the characteristic and the illness. Genetic factors, biochemical factors, life events, demographic variables, and behavioral factors may be examined under the assumption that affective illness is multifactorially determined. Identification of these risk factors by a prospective epidemiologic study in a geographically delimited area is discussed; the risk factor model is compared with the high-risk model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nurnberger</LastName><ForeName>J I</ForeName><Initials>JI</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Jimerson</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Bunney</LastName><ForeName>W E</ForeName><Initials>WE</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6137250</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3497631</PMID><DateCompleted><Year>1987</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>1987</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Changing trends in first admissions and readmissions for mania and schizophrenia in New Zealand, 1974 to 1984.</ArticleTitle><Pagination><MedlinePgn>82-6</MedlinePgn></Pagination><Abstract><AbstractText>From 1974 to 1984 in New Zealand there was a significant decline in first psychiatric admissions for the functional psychoses. This decline is due to decreasing first admission rates for schizophrenia and depressive psychoses, despite an increasing first admission rate for mania. Although a small part of the declining first admission rate for schizophrenia may be due to the increasing diagnosis of mania, this is insufficient to explain all the decline and suggests an actual decline in the incidence of schizophrenia. Over this same period readmissions for functional psychoses increased, with the most marked increase being in manic readmissions. Although a variety of factors influence readmission rates, the marked rise in manic readmissions suggests broadening diagnostic criteria for mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N" Type="Geographic">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="Y">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="Y">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3497631</ArticleId><ArticleId IdType="doi">10.3109/00048678709160903</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26769392</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0957-154X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>History of psychiatry</Title><ISOAbbreviation>Hist Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and its outcomes: two cohorts, 1875-1924 and 1994-2007, compared.</ArticleTitle><Pagination><MedlinePgn>75-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0957154X15624601</ELocationID><Abstract><AbstractText>We compared admission rates and outcomes for bipolar disorder patients using the medical records of patients with a first hospital admission in 1875-1924 retrospectively diagnosed based on International Classification of Diseases (ICD)-10 criteria, and patients with a first admission in 1994-2007. The incidences of first admissions in the historical and contemporary periods are comparable: 1.2 and 1.3 per hundred thousand per year, respectively. Manic episodes constituted a greater proportion of admissions historically, while depressive episodes made up more in the contemporary sample. There is no evidence for a reduction in the mean inter-admission intervals with duration of illness. This study suggests that modern treatments may have decreased lengths of stay in hospital, but at a cost of contributing to more admissions. It also points to a shift in the threshold for admissions. </AbstractText><CopyrightInformation>© The Author(s) 2016.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atigari</LastName><ForeName>Onome V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>North Wales Department of Psychological Medicine, Hergest Unit, Bangor, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>North Wales Department of Psychological Medicine, Hergest Unit, Bangor, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Noury</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>North Wales Department of Psychological Medicine, Hergest Unit, Bangor, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>North Wales Department of Psychological Medicine, Hergest Unit, Bangor, Wales David.Healy54@googlemail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hist Psychiatry</MedlineTA><NlmUniqueID>9013819</NlmUniqueID><ISSNLinking>0957-154X</ISSNLinking></MedlineJournalInfo><CitationSubset>QIS</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="Y">Mental Health Services</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">manic-depressive illness</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">relapse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26769392</ArticleId><ArticleId IdType="pii">0957154X15624601</ArticleId><ArticleId IdType="doi">10.1177/0957154X15624601</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17162830</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>New findings from the Bipolar Collaborative Network: clinical implications for therapeutics.</ArticleTitle><Pagination><MedlinePgn>489-97</MedlinePgn></Pagination><Abstract><AbstractText>In this article, we highlight recent Bipolar Collaborative Network data. We found that childhood-onset bipolar illness is common, often goes untreated for more than a decade, and carries a poor prognosis. During randomized studies of adjunctive medications in depression: 1) Venlafaxine showed higher switch rates than bupropion or sertraline; 2) Tranylcypromine was as well tolerated as lamotrigine; and 3) Modafinil was more effective than placebo. Finally, in treatment of overweight and obesity, topiramate and sibutramine showed equal efficacy but poor tolerability, and zonisamide data showed that it may be useful for mood and weight loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Penn State College of Medicine, Hershey, PA, USA. robert.post@speakeasy.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>42</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17162830</ArticleId><ArticleId IdType="doi">10.1007/s11920-006-0056-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2007 Jun;9(4):426-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17547588</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2005 Jan;5(1):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15853475</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):210-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16449473</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):232-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16449476</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Nov;30(6):1391-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11097079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):310-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jun;64(6):680-90; quiz 738-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12823083</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2152-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16263857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):360-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16081106</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Mar;60(3):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Jan;67(1):115-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16426098</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 May;160(5):883-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12727691</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Apr;85(3):259-66</Citation><ArticleIdList><ArticleId IdType="pubmed">15780695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Jun;7(3):246-59</Citation><ArticleIdList><ArticleId IdType="pubmed">15898962</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Sep;157(9):1501-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10964869</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004;65 Suppl 10:24-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15242329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Mar;63(3):207-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11926719</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):603-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15939838</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Aug;161(8):1447-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15285972</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Jul;148(7):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2053632</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2005 Aug;112(2):105-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15992391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Apr 1;367(9516):1040-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16581389</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Aug;189:124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16880481</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jul;160(7):1252-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12832239</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2003 Dec;5(6):417-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14609495</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Jan 30;141(1):81-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16313969</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1351-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15994719</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15994709</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 May;66(5):617-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15889949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Jan;61(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10695639</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):313-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16449487</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Oct;62(10):1089-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16203954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Aug;62(8):612-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11561933</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9565184</PMID><DateCompleted><Year>1998</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>1998</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>How effective is lithium in the prevention of relapse in bipolar disorder? A prospective naturalistic follow-up study.</ArticleTitle><Pagination><MedlinePgn>61-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The effectiveness of lithium in preventing recurrences of bipolar disorder was examined prospectively for 2 years in two representative samples of bipolar I patients being treated in a comprehensive program following recommended guidelines.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">One hundred and twenty patients were recruited from consecutive admissions to two catchment area psychiatric services (one in the United Kingdom, the other in New Zealand). They were seen at 3-monthly intervals by a member of the research team. Treatment was adjusted according to clinical needs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, two-thirds of the patients had a recurrence. Of the 57 on lithium as sole treatment, 39 (68%) had a further episode; 17 after stopping lithium. The 42 on other mood stabilisers and/or an antipsychotic, with or without lithium, did no better. By contrast, only eight (38%) of the 21 who were taking no prophylactic medication had a recurrence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lithium is much less effective in clinical practice than would be expected from clinical trial results. A major reason for this is poor compliance. Alternative treatment strategies are needed to improve the outcome for bipolar disorder patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silverstone</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Romans</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N" Type="Geographic">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9565184</ArticleId><ArticleId IdType="doi">10.3109/00048679809062707</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22863031</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>White matter integrity within the corpus callosum differentiates late-life bipolar and unipolar depression.</ArticleTitle><Pagination><MedlinePgn>790-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2012.01050.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sexton</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Allan</LastName><ForeName>Charlotte L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Clare E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Ebmeier</LastName><ForeName>Klaus P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1001354</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22863031</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2012.01050.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18455857</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: a case report.</ArticleTitle><Pagination><MedlinePgn>1349-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2008.03.016</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caykoylu</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ekinci</LastName><ForeName>Okan</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kuloglu</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="Y">Substance Withdrawal Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18455857</ArticleId><ArticleId IdType="pii">S0278-5846(08)00095-X</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2008.03.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11058196</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Suicidal ideation and the choice of advance directives by elderly persons with affective disorders.</ArticleTitle><Pagination><MedlinePgn>1447-9</MedlinePgn></Pagination><Abstract><AbstractText>The charts of 191 geriatric psychiatric inpatients with major depressive disorder or bipolar disorder were examined to determine demographic and psychiatric factors associated with the advance directive to have cardiopulmonary resuscitation (CPR) or not to have it in a life-threatening situation. Overall, 48 percent of patients wanted no CPR, 12 percent wanted CPR only, and 41 percent wanted all therapy performed. Patients with suicidal ideation (26 percent of the sample) were significantly more likely to choose not to have CPR. Sixty percent of patients with suicidal ideation chose not to have CPR. Patients with bipolar disorder and patients under age 70 were more likely to choose CPR.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lifton</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Pennsylvania State College of Medicine, Hershey, 17033, USA. idl101@psu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettl</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><CitationSubset>E</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016223" MajorTopicYN="Y">Advance Directives</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016887" MajorTopicYN="Y">Cardiopulmonary Resuscitation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="KIE">105887</OtherID><KeywordList Owner="KIE"><Keyword MajorTopicYN="N">Death and Euthanasia</Keyword><Keyword MajorTopicYN="N">Empirical Approach</Keyword><Keyword MajorTopicYN="N">Mental Health Therapies</Keyword></KeywordList><GeneralNote Owner="KIE">8 refs.</GeneralNote><GeneralNote Owner="KIE">KIE Bib: advance directives</GeneralNote></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11058196</ArticleId><ArticleId IdType="doi">10.1176/appi.ps.51.11.1447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16199055</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Sources of declarative memory impairment in bipolar disorder: mnemonic processes and clinical features.</ArticleTitle><Pagination><MedlinePgn>47-58</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is mounting evidence that declarative memory processes are impaired in patients with bipolar disorder. However, predictors of the observed impairment are not well understood. This study seeks to: (i) better characterize the nature of declarative memory impairment in bipolar disorder, and (ii) determine the relationship between clinical variables and memory function in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">49 adult patients with bipolar disorder in varying mood states and 38 demographically matched healthy participants completed a comprehensive neurocognitive battery assessing general cognitive functioning, processing speed, and declarative memory. The California verbal learning test was used to characterize learning and memory functions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although patients with bipolar disorder utilized a similar semantic clustering strategy to healthy controls, they recalled and recognized significantly fewer words than controls, suggesting impaired encoding of verbal information. In contrast, lack of rapid forgetting suggests relative absence of a storage deficit in bipolar patients. While severity of mood symptomatology and illness duration were not associated with task performance, gender and family history significantly affected memory function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results suggest that declarative memory impairments in bipolar patients: (1) are consistent with deficits in learning, but do not appear to be related to different organizational strategies during learning, and (2) do not appear to be secondary to clinical state, but rather may be associated with the underlying pathophysiology of the illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bearden</LastName><ForeName>Carrie E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Biobehavioral Sciences, University of California Los Angeles, 300 Building Medical Plaza, Suite 2265, Los Angeles, CA 90095, USA. cbearden@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glahn</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Monkul</LastName><ForeName>E Serap</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Najt</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Simerjit</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sanches</LastName><ForeName>Marsal</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Villarreal</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Jair C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR-01346</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012153" MajorTopicYN="N">Retention, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013067" MajorTopicYN="Y">Speech Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="Y">Verbal Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16199055</ArticleId><ArticleId IdType="pii">S0022-3956(05)00101-9</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2005.08.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2149726</PMID><DateCompleted><Year>1991</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>1990</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Effects of different wavelengths in seasonal affective disorder.</ArticleTitle><Pagination><MedlinePgn>209-16</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to compare the relative therapeutic efficacies of three different light sources for treating winter depression. A balanced incomplete block crossover design was employed, whereby all patients (n = 18) were randomly assigned to two out of the three treatment conditions: white, red and blue light. The degree of depression was assessed by the 21-item Hamilton Depression Rating Scale. The data suggest that at a photon density of 2.3 X 10(15) photons/s/cm2, white light has greater therapeutic benefit than red or blue light. It is clear that a larger sample population should be tested to confirm this result. This preliminary finding indicates that light sources currently in use for phototherapy could not be improved by narrowing the wavelengths provided and shifting them towards either end of the visible spectrum.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brainard</LastName><ForeName>G C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Clinical Psychobiology Branch, National Institute of Mental Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherry</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Skwerer</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Waxler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>N E</ForeName><Initials>NE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2149726</ArticleId><ArticleId IdType="pii">0165-0327(90)90052-A</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(90)90052-a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19829091</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3686</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><MedlineDate>2010 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder associated with thenar hypoplasia: is lithium safe?</ArticleTitle><Pagination><MedlinePgn>e135-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MJT.0b013e3181bdc1ec</ELocationID><Abstract><AbstractText>Thenar hypoplasia has been described to occur as a part of radial longitudinal deficiency syndromes and occasionally related to Holt-Oram syndrome in which both cardiac and skeletal abnormalities co-occur. We describe a case with bilateral thenar hypoplasia, which resembles a milder variety of Holt-Oram syndrome, who developed bradycardia after exposure to lithium at therapeutic doses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Praharaj</LastName><ForeName>Samir Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Central Institute of Psychiatry, Kanke, Ranchi, Jharkhand, India. samirpsyche@yahoo.co.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Aleem</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Vinod Kumar</ForeName><Initials>VK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001919" MajorTopicYN="N">Bradycardia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006228" MajorTopicYN="N">Hand Deformities, Congenital</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19829091</ArticleId><ArticleId IdType="doi">10.1097/MJT.0b013e3181bdc1ec</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3761127</PMID><DateCompleted><Year>1986</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3891</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>1986</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Journal of personality assessment</Title><ISOAbbreviation>J Pers Assess</ISOAbbreviation></Journal><ArticleTitle>MMPI predictors of mania among psychiatric inpatients.</ArticleTitle><Pagination><MedlinePgn>248-56</MedlinePgn></Pagination><Abstract><AbstractText>MMPI data from 64 patients with a diagnosis of manic-depressive illness, manic type, were compared with MMPI data from patients in two comparison groups--64 patients with a psychotic diagnosis other than manic-depressive illness, and 64 patients with a variety of psychiatric diagnoses. Manic patients had higher Ma scale scores for MMPI scales that assess personal distress and interpersonal difficulties (e.g., D and Si). Discriminant analysis, with the Ma, D, and Si scales as predictors, correctly classified as manic or not manic 82.5% of the patients in the derivation sample and 74.2% of the patients in the cross-validation sample. Two high-point pairs, Sc-Ma/Ma-Sc and Pa-Ma/Ma-Pa, occurred in the MMPI profiles of almost half of the manic patients but were rarely found among the profiles of other patients. The results of this study support the use of the MMPI in identifying manic patients, particularly when discriminating between mania and other types of psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Clopton</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Keefer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Blyth</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 14517</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pers Assess</MedlineTA><NlmUniqueID>1260201</NlmUniqueID><ISSNLinking>0022-3891</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008950" MajorTopicYN="Y">MMPI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3761127</ArticleId><ArticleId IdType="doi">10.1207/s15327752jpa5002_11</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23351833</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Anomalous subjective experiences in schizophrenia, bipolar disorder, and unipolar depression.</ArticleTitle><Pagination><MedlinePgn>447-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2012.12.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-440X(13)00003-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of the present study was to compare anomalous subjective experiences in patients with schizophrenia, bipolar disorder, and unipolar depression, in order to elucidate differences in subjective experiences and examine their potential clinical correlates in schizophrenia and mood disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The subjective experiences of 78 outpatients with schizophrenia (n=32), bipolar disorder (n=24) and unipolar depression (n=22), and 32 healthy controls were comprehensively assessed using the Frankfurt Complaint Questionnaire (FCQ).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The FCQ total score was significantly higher in the schizophrenia and depression groups than in the healthy control group. There were no significant differences in the FCQ total or subscale scores among the schizophrenia, unipolar depression, and bipolar disorder groups. In the schizophrenia group, the Positive and Negative Syndrome Scale negative factor score was a significant negative predictor of the severity of subjective experiences assessed by the FCQ total score. Disruption of subjective experiences in patients with unipolar depression was associated with greater severity of depressive symptoms and younger age. In the bipolar disorder group, women reported more disruptions in subjective experience.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anomalous subjective experiences measured by the FCQ are not specific to schizophrenia, and the severity of these experiences in unipolar depression is substantially high. The finding of a dissimilar pattern of predictors of subjective experiences across different diagnostic groups suggests the complexity and variety of factors contributing to anomalous subjective experiences in schizophrenia and mood disorders.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong-Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Gil Medical Center, Gachon University, 1198 Guwol-Dong, Namdong-Gu, Incheon, 405-760, South Korea. jhnp@chol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hee</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinyoung</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010465" MajorTopicYN="Y">Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23351833</ArticleId><ArticleId IdType="pii">S0010-440X(13)00003-5</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2012.12.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30149091</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><PubDate><Year>2019</Year><Month>03</Month><Day>08</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>23-29</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(18)30429-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2018.08.023</ELocationID><Abstract><AbstractText>Shared genetic vulnerability between schizophrenia (SCZ) and bipolar disorder (BP) was demonstrated, but the genetic underpinnings of specific symptom domains are unclear. This study investigated which genes and gene sets may modulate specific psychopathological domains and if genome-wide significant loci previously associated with SCZ or BP may play a role. Genome-wide data were available in patients with SCZ (n = 226) or BP (n = 228). Phenotypes under investigation were depressive and positive symptoms severity, suicidal ideation, onset age and substance use disorder comorbidity. Genome-wide analyses were performed at gene and gene set level, while 148 genome-wide significant loci previously associated with SCZ and/or BP were investigated. Each sample was analyzed separately then a meta-analysis was performed. SH3GL2 and CLVS1 genes were associated with suicidal ideation in SCZ (p = 5.62e-08 and 0.01, respectively), the former also in the meta-analysis (p = .01). SHC4 gene was associated with depressive symptoms severity in BP (p = .003). A gene set involved in cellular differentiation (GO:0048661) was associated with substance disorder comorbidity in the meta-analysis (p = .03). Individual loci previously associated with SCZ or BP did not modulate the phenotypes of interest. This study provided confirmatory and new findings. SH3GL2 (endophilin A1) showed a role in suicidal ideation that may be due to its relevance to the glutamate system. SHC4 regulates BDNF-induced MAPK activation and was previously associated with depression. CLVS1 is involved in lysosome maturation and was for the first time associated with a psychiatric trait. GO:0048661 may mediate the risk of substance disorder through an effect on neurodevelopment/neuroplasticity.</AbstractText><CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corponi</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonassi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy; Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albani</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frustaci</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barnet, Enfield and Haringey Mental Health NHS Trust, St.Ann's Hospital, St.Ann's Road, N15 3 TH London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducci</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mental Health Department, ASL Roma 1, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Biologia, Universita' di Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccia</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Hygiene, Institute of Public Health, Universita' Cattolica del Sacro Cuore, Fondazione Policlinico "Agostino Gemelli" IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbri</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cross-disorder</Keyword><Keyword MajorTopicYN="Y">Gene</Keyword><Keyword MajorTopicYN="Y">Genetics</Keyword><Keyword MajorTopicYN="Y">Pathway</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30149091</ArticleId><ArticleId IdType="pii">S0278-5846(18)30429-9</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2018.08.023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12692779</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1562-2975</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Reconsidering the classification of schizophrenia and manic depressive illness--a critical analysis and new conceptual model.</ArticleTitle><Pagination><MedlinePgn>81-92</MedlinePgn></Pagination><Abstract><AbstractText>The idea of 'disease entity' in psychiatry and the nosologic map of insanity with the distinction between dementia praecox (schizophrenia since Bleuler 1911) and manic depressive insanity, originally developed by Emil Kraepelin (1986), is an important landmark in the history of psychiatry (Jablensky 1995). This classification, however, has been vigorously debated throughout the years, and new evidence emerging from epidemiological, clinical, genetic and biological research demonstrates that the two nosological categories have distinct features as well as share many similarities in their risk factors, genetic predisposition, brain pathology, neurophysiology, clinical phenomenology and response to treatment, thus raising questions about the validity of the categorical classification of psychoses. In this paper we examine some of the similarities and differences between schizophrenia and bipolar illness emerging from recent biological and clinical research and attempt to clarify major inherent logical contradictions in the application of the 'disease' model of psychiatric diagnosis to the categorical classification of schizophrenia and bipolar illness. Then we examine how similar predicaments have been resolved in other natural classification systems, namely the biological classification of species and the periodic table of the elements. Finally we propose a hypothetical conceptual approach to the classification of psychoses that has been greatly informed by the organizing principle underlying the periodic table of the elements, and is distinct from the 'disease' model of psychiatric classification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boteva</LastName><ForeName>Kalina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5-T32-MH19111-12</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>111</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12692779</ArticleId><ArticleId IdType="doi">10.3109/15622970309167956</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15024812</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0749-0690</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinics in geriatric medicine</Title><ISOAbbreviation>Clin Geriatr Med</ISOAbbreviation></Journal><ArticleTitle>Late-life mood disorders.</ArticleTitle><Pagination><MedlinePgn>777-97, vii</MedlinePgn></Pagination><Abstract><AbstractText>Mental disorders are not uncommon in late life. Although most psychiatric disorders occur less frequently in older populations compared with populations of younger adults, more than 10% of older adults have one or more psychiatric disorders. In addition, many older adults present with symptoms that do not meet the criteria for a specific disorder but nevertheless are clinically significant and affect quality of life. In this article the authors summarize the epidemiologic data for five psychiatric disorders and their subclinical forms: depression, anxiety, dementia, schizophrenia, and alcoholism. Also included is a discussion of risk factors and outcomes of these disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Nebraska Medical Center, 985580 Nebraska Medical Center, Omaha, NE 68198-5580, USA. wjburke@unmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wengel</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Geriatr Med</MedlineTA><NlmUniqueID>8603766</NlmUniqueID><ISSNLinking>0749-0690</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="Y">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>75</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15024812</ArticleId><ArticleId IdType="pii">S0749-0690(03)00041-7</ArticleId><ArticleId IdType="doi">10.1016/s0749-0690(03)00041-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31759285</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Role of transcranial direct current stimulation in bipolar depression: A case report.</ArticleTitle><Pagination><MedlinePgn>101873</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(19)31179-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2019.101873</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baliga</LastName><ForeName>Sachin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sreeraj</LastName><ForeName>Vanteemar S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India. Electronic address: vs8sreeraj@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parlikar</LastName><ForeName>Rujuta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Dev</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhabra</LastName><ForeName>Harleen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatasubramanian</LastName><ForeName>Ganesan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>WISER program, Department of Psychiatry and Translational psychiatry laboratory, Neurobiology Research Centre,National Institute of mental health and neurosciences (NIMHANS), Bengaluru, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014149">Tranquilizing Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014149" MajorTopicYN="N">Tranquilizing Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065908" MajorTopicYN="Y">Transcranial Direct Current Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest None. All the authors assure that there are no commercial or financial involvements that might present an appearance of a conflict of interest in connection with this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31759285</ArticleId><ArticleId IdType="pii">S1876-2018(19)31179-7</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2019.101873</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">431799</PMID><DateCompleted><Year>1979</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>1979</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>HL-A antigens and the response to prophylactic lithium.</ArticleTitle><Pagination><MedlinePgn>114-8</MedlinePgn></Pagination><Abstract><AbstractText>82 consecutive patients checked at the out-patient clinic of the Psychiatric Department of the Umeå University were typed for HL-A antigens. The patients belonged to the diagnostic subgroups: bipolar (manic-depressive) psychosis (n = 33), unipolar recurrent depressive psychosis (n = 29) and cycloid psychosis (n = 20) and all had been on lithium treatment for at least 6 months. By comparing the group of those who did not relapse on lithium therapy (n = 48) with the group of those who did relapse (n = 34) there was a significantly higher frequency of the HL-A A3 antigens among those who did relapse, and none of those who did not relapse were found to have the HL-A B18 antigens. The results suggest a possible interference between HL-A antigens and response to lithium treatment. However, a large number of antigens were tested and a small number of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perris</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Strandman</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wählby</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="Y">HLA Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">431799</ArticleId><ArticleId IdType="doi">10.1159/000117671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26244883</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Cerebral Correlates of Abnormal Emotion Conflict Processing in Euthymic Bipolar Patients: A Functional MRI Study.</ArticleTitle><Pagination><MedlinePgn>e0134961</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0134961</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with bipolar disorder experience cognitive and emotional impairment that may persist even during the euthymic state of the disease. These persistent symptoms in bipolar patients (BP) may be characterized by disturbances of emotion regulation and related fronto-limbic brain circuitry. The present study aims to investigate the modulation of fronto-limbic activity and connectivity in BP by the processing of emotional conflict.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fourteen euthymic BP and 13 matched healthy subjects (HS) underwent functional magnetic resonance imaging (fMRI) while performing a word-face emotional Stroop task designed to dissociate the monitoring/generation of emotional conflict from its resolution. Functional connectivity was determined by means of psychophysiological interaction (PPI) approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative to HS, BP were slower to process incongruent stimuli, reflecting higher amount of behavioral interference during emotional Stroop. Furthermore, BP showed decreased activation of the right dorsolateral prefrontal cortex (DLPFC) during the monitoring and a lack of bilateral amygdala deactivation during the resolution of the emotional conflict. In addition, during conflict monitoring, BP showed abnormal positive connectivity between the right DLPFC and several regions of the default mode network.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, our results highlighted dysfunctional processing of the emotion conflict in euthymic BP that may be subtended by abnormal activity and connectivity of the DLPFC during the conflict monitoring, which, in turn, leads to failure of amygdala deactivation during the resolution of the conflict. Emotional dysregulation in BP may be underpinned by a lack of top-down cognitive control and a difficulty to focus on the task due to persistent self-oriented attention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Favre</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Univ. Grenoble Alpes, LPNC, CNRS UMR 5105, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polosan</LastName><ForeName>Mircea</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU de Grenoble, Pôle Psychiatrie et Neurologie, Centre Expert en Troubles Bipolaires, Université Joseph Fourier, Grenoble, France; Univ. Grenoble Alpes, GIN, INSERM, CHU de Grenoble, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pichat</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Univ. Grenoble Alpes, LPNC, CNRS UMR 5105, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bougerol</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CHU de Grenoble, Pôle Psychiatrie et Neurologie, Centre Expert en Troubles Bipolaires, Université Joseph Fourier, Grenoble, France; Univ. Grenoble Alpes, GIN, INSERM, CHU de Grenoble, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baciu</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Grenoble Alpes, LPNC, CNRS UMR 5105, Grenoble, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01821469</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003220" MajorTopicYN="Y">Conflict, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011603" MajorTopicYN="N">Psychophysiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057190" MajorTopicYN="N">Stroop Test</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26244883</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0134961</ArticleId><ArticleId IdType="pii">PONE-D-15-04637</ArticleId><ArticleId IdType="pmc">PMC4526683</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1999 Nov;10(5):607-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10547338</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Jan 15;24(2):539-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15627596</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(8):e6726</Citation><ArticleIdList><ArticleId IdType="pubmed">21949675</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 May;156(5):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10327898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;165:182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24882198</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 May 30;159(1-2):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18295902</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Sep 21;51(6):871-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16982430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):326-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22631618</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Sep 1;62(5):429-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17210143</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2005 May;9(5):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15866151</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):1023-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Dec 30;214(3):285-95</Citation><ArticleIdList><ArticleId IdType="pubmed">24156926</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2002 Mar;3(3):201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2012 Feb;16(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22245618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2001 May;30(2):319-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11394996</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Cogn Affect Neurosci. 2009 Sep;4(3):305-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19307251</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Dec 15;44(12):1219-28</Citation><ArticleIdList><ArticleId IdType="pubmed">9861465</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Jul;19(3):1233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):63-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19133967</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Aug 30;223(2):84-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24862389</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1998 Jan;7(1):30-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9500830</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2001 Jul;108(3):624-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11488380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2000 Oct;23(10):475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11006464</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Jun 1;56(3):1677-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21352930</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11259662</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 5:58-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16225562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2007 Oct 8;18(15):1583-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17885606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Jan;15(1):273-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Aug;171(8):829-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2008 Mar;1124:1-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2010 Jul;122(4):7-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20675966</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2003 Nov-Dec;29(6):499-505</Citation><ArticleIdList><ArticleId IdType="pubmed">15029084</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 May;19(1):200-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12781739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Oct 1;37(4):1083-90; discussion 1097-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Mar;35(1):430-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17239620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):28-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16411978</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2013 Oct 10;7:666</Citation><ArticleIdList><ArticleId IdType="pubmed">24124416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15117401</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16595351</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1055-0496</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><MedlineDate>2006 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>The American journal on addictions</Title><ISOAbbreviation>Am J Addict</ISOAbbreviation></Journal><ArticleTitle>Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants.</ArticleTitle><Pagination><MedlinePgn>138-43</MedlinePgn></Pagination><Abstract><AbstractText>The validity of a primary/secondary substance use disorder (SUD) distinction was evaluated in the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder. Patients with primary SUD (n = 116) were compared with those with secondary SUD (n = 275) on clinical course variables. Patients with secondary SUD had fewer days of euthymia, more episodes of mania and depression, and a greater history of suicide attempts. These findings were fully explained by variations in age of onset of bipolar disorder. The order of onset of SUDs was not linked to bipolar outcomes when age of onset of bipolar disorder was statistically controlled. The primary/secondary distinction for SUD is not valid when variations in the age of onset of the non-SUD are linked to course characteristics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fossey</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oklahoma College of Medicine-Tulsa, Tulsa, Oklahoma 74135, USA. mark-fossey@ouhsc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Steve R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Gyulai</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Neel</LastName><ForeName>Jackie L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Roger D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><CollectiveName>Step-BD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Addict</MedlineTA><NlmUniqueID>9208821</NlmUniqueID><ISSNLinking>1055-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16595351</ArticleId><ArticleId IdType="pii">H56554683004J47R</ArticleId><ArticleId IdType="doi">10.1080/10550490500528423</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23527945</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0451</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>12</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>AIDS care</Title><ISOAbbreviation>AIDS Care</ISOAbbreviation></Journal><ArticleTitle>Prevalence of bipolar disorder in a HIV-infected outpatient population.</ArticleTitle><Pagination><MedlinePgn>1499-503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540121.2013.779625</ELocationID><Abstract><AbstractText>This study assesses the prevalence of bipolar disorder (BD) among 196 HIV-infected adult outpatients attending in a specialized unit in Fortaleza, Brazil. Patients were interviewed with the Mood Disorder Questionnaire (MDQ), the Mini International Neuropsychiatric Interview (MINI), the Alcohol Use Disorders Identification Test (AUDIT), and a socio-demographic questionnaire based on WHO's behavioral surveillance surveys. Positive MDQ screening was found in 13.2% (N=26) and the BD diagnosis was confirmed in 8.1% (N=16) of the sample. There is an almost four times higher prevalence of BD among the HIV-infected patients of the sample (8.1%) than in the general population from the USA (2.1%). The prevalence of BD type I in the HIV patients was 5.6% (N=11) which is almost six times higher than the US general population (1%). The odds ratios of sexual behaviors and substance abuse variables correlated with BD were calculated. The variables associated with the diagnoses of BD were sex with commercial partners, sex outside the primary relationship, alcohol use disorders, and illicit drug abuse. The most common psychiatric comorbidity in the BD group was substance abuse (61.5%). A better understanding of psychiatric comorbidities and behavioral aspects of HIV-positive patients may help in improving long-term outcome of these patients. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Sousa Gurgel</LastName><ForeName>Wagner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>a Affective Disorders Study Group (GETA), Department of Clinical Medicine , Federal University of Ceará (UFC) , Fortaleza , CE , Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Carneiro</LastName><ForeName>Alexandre Henrique</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Barreto Rebouças</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Negreiros de Matos</LastName><ForeName>Karla Julianne</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>do Menino Jesus Silva Leitão</LastName><ForeName>Terezinha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>de Matos e Souza</LastName><ForeName>Fábio Gomes</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><CollectiveName>Affective Disorders Study Group (GETA)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Care</MedlineTA><NlmUniqueID>8915313</NlmUniqueID><ISSNLinking>0954-0121</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="N">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012309" MajorTopicYN="N">Risk-Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23527945</ArticleId><ArticleId IdType="doi">10.1080/09540121.2013.779625</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8104389</PMID><DateCompleted><Year>1993</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>150</Volume><Issue>10</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depressive mania associated with nonresponse to antimanic agents.</ArticleTitle><Pagination><MedlinePgn>1548-51</MedlinePgn></Pagination><Abstract><AbstractText>Of 39 patients consecutively admitted for the treatment of primary mania, 21 (53.8%) simultaneously met the Research Diagnostic Criteria for major depressive disorder ("mixed" or "depressive" mania). Only nine (42.9%) of the 21 patients with depressive mania responded to antimanic agents. In contrast, 16 (88.9%) of the 18 patients with pure mania responded to these drugs. This finding is consistent with previous reports suggesting that the mixed state is a virulent form of mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dilsaver</LastName><ForeName>S C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Harris County Psychiatric Center, Department of Psychiatry and Behavioral Sciences, University of Texas School of Medicine, Houston 77021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Shoaib</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Bowers</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Halle</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8104389</ArticleId><ArticleId IdType="doi">10.1176/ajp.150.10.1548</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11097169</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>250</Volume><Issue>5</Issue><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Suicidality in bipolar compared to unipolar depressed inpatients.</ArticleTitle><Pagination><MedlinePgn>257-61</MedlinePgn></Pagination><Abstract><AbstractText>The aim of the present analyses was to evaluate differences in suicidality (past suicide attempts, suicidal thoughts at time of admission and completed suicides during the hospital stay) between bipolar and unipolar depressed inpatients. Apart from a higher frequency of past suicide attempts in bipolar depressed patients (26.6% in bipolar vs. 17.8% in unipolar patients), findings do not indicate any further differences in suicidality (suicidal thoughts (about 40% in both groups) and completed suicides during the hospital stay (0.8% in both groups)) between bipolar and unipolar patients. Factors with a predictive value for suicidal thoughts at the time of admission were a positive family history for affective disorders, past suicide attempts, and the depressive and paranoid hallucinatory syndrome (all associated with an increased risk). Female gender, an older age at hospitalisation and a longer duration of the illness were found to be associated with a lower probability for having suicidal tendencies at the time of admission. The risk for committing suicide during the hospital stay was increased if the patients had a history of past suicide attempts and suicidal thoughts at the time of admission. A more pronounced depressive syndrome at time of admission was slightly associated with a lower risk of committing suicide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bottlender</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Psychiatrische Klinik der Ludwig-Maximilians-Universität, München. bottlend@psy.med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jäger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Möller</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11097169</ArticleId><ArticleId IdType="doi">10.1007/s004060070016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17272739</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>174-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors report on the relationship between cognitive functioning and instrumental activities of daily living (IADLs) in elderly, clinically euthymic adults with bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with bipolar disorder (age range: 61-86 years) were administered comprehensive neuropsychologic testing. Structured in-home performance-based assessments of IADLs were performed in 19 of these patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative to age-equated comparators, bipolar subjects performed worse in information-processing speed and executive functioning. IADL performance was strongly correlated with these cognitive domains.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In euthymic elderly patients with bipolar disorder, decrements in information processing speed and executive functioning characterize cognitive function and are associated with poorer IADL performance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gildengers</LastName><ForeName>Ariel G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Advanced Center for Intervention and Services Research for Late-Life Disorders, Department of Psychiatry, Bipolar Disorder Center for Pennsylvanians, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butters</LastName><ForeName>Meryl A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Chisholm</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Margo B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Bhalla</LastName><ForeName>Rishi K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Seligman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dew</LastName><ForeName>Mary Amanda</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH 073772</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH01684</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH069430</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH072947</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH52247</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH19986</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH71944</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17272739</ArticleId><ArticleId IdType="pii">15/2/174</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e31802dd367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28711681</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Chlorpheniramine dependence presenting as mania.</ArticleTitle><Pagination><MedlinePgn>29-30</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(17)30457-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2017.07.007</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Soumitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, NIMHANS, Bengaluru, India. Electronic address: soumitra_nimhans@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palappallil</LastName><ForeName>Dhanya S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Government TD Medical College, Alappuzha, India. Electronic address: drspdhanya@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B C</LastName><ForeName>Malathesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NIMHANS, India. Electronic address: bc.malathesh@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatterjee</LastName><ForeName>Seshadri Sekhar</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>NIMHANS, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018682">GABA Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U6IO1965U</RegistryNumber><NameOfSubstance UI="D002744">Chlorpheniramine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002744" MajorTopicYN="N">Chlorpheniramine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018682" MajorTopicYN="N">GABA Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006634" MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28711681</ArticleId><ArticleId IdType="pii">S1876-2018(17)30457-4</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2017.07.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2175146</PMID><DateCompleted><Year>1991</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6314</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>2</Issue><PubDate><Year>1990</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Acta neurologica Scandinavica</Title><ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation></Journal><ArticleTitle>Subclinical lithium neurotoxicity: correlation of neural conduction abnormalities and serum lithium level in manic-depressive patients with lithium treatment.</ArticleTitle><Pagination><MedlinePgn>82-6</MedlinePgn></Pagination><Abstract><AbstractText>Nerve conduction velocities (NCVs) and multimodality evoked potentials were studies in 28 manic-depressive patients under lithium prophylaxis with serum lithium levels between 0.320 and 0.980 mEq/L. Slowing of motor and sensory NCVs and prolonged central neural conduction times obtained from somatosensory and brainstem auditory evoked potentials were found to correlate with serum lithium levels. Lithium-induced changes in cell membrane conductivity and in the synaptic transmission are considered responsible for the neurotoxic effects of lithium.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Y C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Taiwan University Hospital, Taipei, R.o.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>H N</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Neurol Scand</MedlineTA><NlmUniqueID>0370336</NlmUniqueID><ISSNLinking>0001-6314</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001827" MajorTopicYN="N">Body Height</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2175146</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0404.1990.tb01593.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12113208</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0306-624X</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of offender therapy and comparative criminology</Title><ISOAbbreviation>Int J Offender Ther Comp Criminol</ISOAbbreviation></Journal><ArticleTitle>Use of the Rorschach in forensic settings for treatment planning and monitoring.</ArticleTitle><Pagination><MedlinePgn>294-307</MedlinePgn></Pagination><Abstract><AbstractText>Forensic psychiatric patients exhibit complex clinical issues that are neither readily understood by staff nor necessarily responsive to traditional psychotherapy or treatment milieu approaches. Individualized treatment planning identifies treatment needs and matches them to treatment services, thereby increasing the opportunity for a positive therapeutic outcome. The nature of the Rorschach, particularly that it bypasses volitional resources, enables observation and quantification of personality processes, making the Rorschach uniquely suited for treatment planning in forensic settings. In this article, the authors review relevant Rorschach literature, address the importance of incorporating Rorschach data into the assessment process, and discuss how Rorschach data fit into a thorough assessment that includes historical, clinical, dispositional, and contextual information. The authors offer two case examples to illustrate how Rorschach data are integrated in forensic treatment planning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jumes</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Competency Program, North Texas State Hospital, Vernon Campus, P.O. Box 2231, Vernon, Texas 76384, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oropeza</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>B Thomas</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Gacono</LastName><ForeName>Carl B</ForeName><Initials>CB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Offender Ther Comp Criminol</MedlineTA><NlmUniqueID>0333601</NlmUniqueID><ISSNLinking>0306-624X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005554" MajorTopicYN="Y">Forensic Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012392" MajorTopicYN="Y">Rorschach Test</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12113208</ArticleId><ArticleId IdType="doi">10.1177/0306624X02463004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6693024</PMID><DateCompleted><Year>1984</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0163-8343</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>1984</Year><Month>Jan</Month></PubDate></JournalIssue><Title>General hospital psychiatry</Title><ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Acute psychosis in a 45-year-old man with bipolar disorder and primary Epstein-Barr virus infection: a case report.</ArticleTitle><Pagination><MedlinePgn>13-5</MedlinePgn></Pagination><Abstract><AbstractText>A 45-year-old physician with bipolar disorder presented with an acute organic psychosis, fever, and hematologic and serologic findings of a primary Epstein-Barr virus infection. Pathogenesis was complicated by the history of discontinued lithium therapy prior to the psychosis. The patient recovered completely. Literature concerning psychosis and infectious mononucleosis is reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gen Hosp Psychiatry</MedlineTA><NlmUniqueID>7905527</NlmUniqueID><ISSNLinking>0163-8343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007244" MajorTopicYN="N">Infectious Mononucleosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6693024</ArticleId><ArticleId IdType="pii">0163-8343(84)90053-7</ArticleId><ArticleId IdType="doi">10.1016/0163-8343(84)90053-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10645326</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>175</Volume><PubDate><Year>1999</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological function in euthymic patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>246-51</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The assumption that patients with bipolar disorder make a full inter-episode recovery has been challenged by limited evidence that suggests that neuropsychological dysfunction in bipolar disorder may persist beyond episodes of illness.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To test the hypothesis that patients with euthymic bipolar disorder show neuropsychological impairment.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A battery of neuropsychological tests (assessed attention, working memory, learning and executive function) was administered to three matched groups of subjects: good-outcome patients with bipolar disorder (n = 21); poor-outcome patients with bipolar disorder (n = 20); controls (n = 20). All patients were clinically euthymic, although some had low levels of depressive symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients performed worse than controls on a number of neuropsychological tests. When age, premorbid IQ and depressive symptoms were controlled for, the results indicated impairment of executive function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings provide good evidence for the existence of neuropsychological impairment in patients with euthymic bipolar disorder, although the possible effect of medication should not be overlooked. This may be of clinical relevance and raises questions about the course and outcome of the illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrier</LastName><ForeName>I N</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Newcastle, Newcastle upon Tyne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>T P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>25</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>25</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10645326</ArticleId><ArticleId IdType="pii">S0007125000153760</ArticleId><ArticleId IdType="doi">10.1192/bjp.175.3.246</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18061327</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder".</ArticleTitle><Pagination><MedlinePgn>595-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pae</LastName><ForeName>Chi-Un</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Changsu</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Patkar</LastName><ForeName>Ashwin A</ForeName><Initials>AA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1548-9</RefSource><PMID Version="1">17630063</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18061327</ArticleId><ArticleId IdType="pii">S0278-5846(07)00379-X</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2007.10.012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5807757</PMID><DateCompleted><Year>1969</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>1969</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Manic-depressive illness, diabetes mellitus, and lithium carbonate.</ArticleTitle><Pagination><MedlinePgn>478-85</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Velde</LastName><ForeName>C D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002254">Carbonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002254" MajorTopicYN="N">Carbonates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="Y">Diabetes Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005951" MajorTopicYN="Y">Glucose Tolerance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1969</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1969</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1969</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5807757</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1969.01740220094011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24269194</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lifetime mania is related to post-traumatic stress symptoms in high school students exposed to the 2009 L'Aquila earthquake.</ArticleTitle><Pagination><MedlinePgn>357-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2013.08.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-440X(13)00280-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar patients seem to be at high risk of trauma exposure and, when exposed, of PTSD. When comorbid, PTSD has shown a negative impact on the course of the bipolar illness. Conversely, a correlation between even manic symptoms and an increased risk for suicide has also been reported in PTSD patients. The aim of this study was to investigate the relationships between lifetime mood spectrum symptoms and PTSD in a sample of earthquake survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 475 young adults who survived the L'Aquila 2009 earthquake, 21months earlier, were assessed by the Moods Spectrum-Self Report (MOODS-SR) and the Trauma and Loss Spectrum Self Report (TALS-SR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly higher MOODS-SR and TALS-SR domain scores were found in PTSD survivors compared to those without. The mood depressive (O.R.=1.17, 95% CI: 1.10-1.25), cognition depressive (O.R.=1.07, 95% CI: 1.01-1.14) and energy manic (O.R.=1.13, 95% CI: 1.02-1.25) MOODS-SR domains were significantly associated with an increased likelihood of PTSD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data corroborate the strong relationship between mood disorder and PTSD highlighting a relationship between lifetime depressive and manic symptoms and PTSD, with a particular impact of the latter on the number of traumatic exposures and maladaptive behaviors.</AbstractText><CopyrightInformation>© 2014.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dell'osso</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratta</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Experimental Medicine, University of L'Aquila, Italy, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conversano</LastName><ForeName>Ciro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massimetti</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Kareen K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Experimental Medicine, University of L'Aquila, Italy, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmassi</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: ccarmassi@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004190" MajorTopicYN="N">Disasters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055866" MajorTopicYN="N">Earthquakes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24269194</ArticleId><ArticleId IdType="pii">S0010-440X(13)00280-0</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2013.08.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27862615</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical psychology &amp; psychotherapy</Title><ISOAbbreviation>Clin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>The Reciprocal Relationship between Bipolar Disorder and Social Interaction: A Qualitative Investigation.</ArticleTitle><Pagination><MedlinePgn>911-918</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpp.2055</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence suggests that social support can influence relapse rates, functioning and various clinical outcomes in people with bipolar disorder. Yet 'social support' is a poorly defined construct, and the mechanisms by which it affects illness course in bipolar disorder remain largely unknown. Key aims of this study were to ascertain which facets of social interaction affect mood management in bipolar disorder, and how symptoms of bipolar disorder can influence the level of support received.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Semi-structured qualitative interviews were conducted with 20 individuals with bipolar disorder. Questions were designed to elicit: the effects of social interaction upon the management and course of bipolar disorder; and the impact of bipolar disorder upon social relationships. An inductive thematic analysis was used to analyse the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Empathy and understanding from another person can make it easier to cope with bipolar disorder. Social interaction can also provide opportunities to challenge negative ruminative thoughts and prevent the onset of a major mood episode. The loss of social support, particularly through bereavement, creates a loss of control and can trigger mania or depression. Hypomanic symptoms can facilitate new social connections, whereas disinhibited and risky behaviour exhibited during mania can cause the breakdown of vital relationships.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An in-depth clinical formulation of an individual's perceptions of how their illness affects and is affected by social interaction is crucial to understanding psychosocial factors which influence mood management. These results have clear application in interventions which aim to promote improved wellbeing and social functioning in bipolar disorder. Copyright © 2016 John Wiley &amp; Sons, Ltd.</AbstractText><AbstractText Label="KEY PRACTITIONERS MESSAGES" NlmCategory="UNASSIGNED">The relationship between bipolar-related experiences and social interaction is complex and multi-faceted. Bipolar disorder can damage social relationships and create a loss of social control via extreme mood states, but it can also offer a social advantage through elevated self-confidence during hypomania and enhanced resilience post-recovery. Positive social experiences can facilitate better personal coping and enhanced mood management, whilst negative social experiences can trigger the onset of acute mood episodes. A comprehensive formulation of the reciprocal links between facets of bipolar disorder and characteristics of interpersonal relationships should be used to guide psychosocial interventions that aim to enhance emotion regulation and improve functioning.</AbstractText><CopyrightInformation>Copyright © 2016 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gooding</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dempsey</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Health Psychology, Staffordshire University, Stoke-on-Trent, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Lancaster University, Lancaster, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Psychol Psychother</MedlineTA><NlmUniqueID>9416196</NlmUniqueID><ISSNLinking>1063-3995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005069" MajorTopicYN="N">Evaluation Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="Y">Social Support</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Caregiver</Keyword><Keyword MajorTopicYN="N">Family</Keyword><Keyword MajorTopicYN="N">Psychosocial</Keyword><Keyword MajorTopicYN="N">Social</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>02</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27862615</ArticleId><ArticleId IdType="doi">10.1002/cpp.2055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26420497</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2015</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Mandatory implementation of NICE Guidelines for the care of bipolar disorder and other conditions in England and Wales.</ArticleTitle><Pagination><MedlinePgn>246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-015-0464-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a common long-term mental health condition characterised by episodes of mania or hypomania and depression resulting in disability, early death, and high health and society costs. Public money funds the National Institute of Healthcare and Clinical Excellence (NICE) to produce clinical guidelines by systematically identifying the most up to date research evidence and costing its main recommendations for healthcare organisations and professionals to follow in England and Wales. Most governments, including those of England and Wales, need to improve healthcare but at reduced cost. There is evidence, particularly in bipolar disorder, that systematically following clinical guidelines achieves these outcomes.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">NICE clinical guidelines, including those regarding bipolar disorder, remain variably implemented. They give clinicians and patients a non-prescriptive basis for deciding their care. Despite the passing of the Health and Social Care Act in 2012 in England requiring all healthcare organisations to consider NICE clinical guidelines in commissioning, delivering, and inspecting healthcare services, healthcare organisations in the National Health Service may ignore them with little accountability and few consequences. There is no mechanism to ensure that healthcare professionals know or consider them. Barriers to their implementation include the lack of political and professional leadership, the complexity of the organisation of care and policy, mistrust of some processes and recommendations of clinical guidelines, and a lack of a clear implementation model, strategy, responsibility, or accountability. Mitigation to these barriers is presented herein.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">The variability, safety, and quality of healthcare might be improved and its cost reduced if the implementation of NICE clinical guidelines, such as those for bipolar disorder, were made the minimum starting point for clinical decision-making and mandatory responsibilities of all healthcare organisations and professionals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morriss</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Psychiatry and Community Mental Health, University of Nottingham, Nottingham, UK. richard.morriss@nottingham.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N">Wales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26420497</ArticleId><ArticleId IdType="doi">10.1186/s12916-015-0464-7</ArticleId><ArticleId IdType="pii">10.1186/s12916-015-0464-7</ArticleId><ArticleId IdType="pmc">PMC4588679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2012 Dec 15;380(9859):2163-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23245607</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Heart. 2015 Feb 19;2(1):e000151</Citation><ArticleIdList><ArticleId IdType="pubmed">25722859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2001 Sep;16(9):606-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2015;10:43</Citation><ArticleIdList><ArticleId IdType="pubmed">25888854</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2012;7:97</Citation><ArticleIdList><ArticleId IdType="pubmed">23068016</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Med (Lond). 2013 Feb;13(1):13-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23472486</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014;9(12):e113715</Citation><ArticleIdList><ArticleId IdType="pubmed">25436639</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010;(3):CD005470</Citation><ArticleIdList><ArticleId IdType="pubmed">20238340</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Psychother. 2008 Dec;81(Pt 4):437-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18215339</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2002 Nov;55(10):1771-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12383461</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Care Manage Rev. 2002 Summer;27(3):35-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12146782</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2015;10:93</Citation><ArticleIdList><ArticleId IdType="pubmed">26122560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sociol Health Illn. 2006 Nov;28(7):951-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17163861</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Neurosurg. 2012 Jun;26(3):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22482926</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 May;206(5):357-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25934299</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2012 Apr;38(2):126-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22516270</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2006 Jan;51(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16491979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Oct 8;378(9799):1306-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21851976</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Apr;206(4):263-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25833865</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;347:f4771</Citation><ArticleIdList><ArticleId IdType="pubmed">23900822</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Prim Care. 2013;21(4):237-46</Citation><ArticleIdList><ArticleId IdType="pubmed">24041141</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;346:f3830</Citation><ArticleIdList><ArticleId IdType="pubmed">23771225</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2012 Jun;16(29):1-271, iii-iv</Citation><ArticleIdList><ArticleId IdType="pubmed">22687263</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;347:f4876</Citation><ArticleIdList><ArticleId IdType="pubmed">23920259</ArticleId></ArticleIdList></Reference><Reference><Citation>MedGenMed. 2001 Mar 5;3(2):2</Citation><ArticleIdList><ArticleId IdType="pubmed">11549951</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Prim Care. 2012;20(2):93-103</Citation><ArticleIdList><ArticleId IdType="pubmed">22824562</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2012 Nov 26;172(21):1628-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23089902</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2013 Sep;51(9):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">23872702</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2013;8:112</Citation><ArticleIdList><ArticleId IdType="pubmed">24063756</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Mar;14(15):1-98</Citation><ArticleIdList><ArticleId IdType="pubmed">20334748</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Danub. 2009 Jun;21(2):224-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19556953</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2013 May 28;3(5):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23793669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Evid Based Med. 2014 Feb;7(1):52-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25155567</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Mar;202(3):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23349295</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2014;349:g5673</Citation><ArticleIdList><ArticleId IdType="pubmed">25258392</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Gen Pract. 2001 Sep;51(470):737-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11593835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Mar 17;379(9820):1005-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22305767</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2012 Feb;74(3):297-304</Citation><ArticleIdList><ArticleId IdType="pubmed">22014420</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr. 2013 Feb;32(1):73-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22687466</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2013;13:234</Citation><ArticleIdList><ArticleId IdType="pubmed">24066860</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Feb 20;318(7182):527-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10024268</ArticleId></ArticleIdList></Reference><Reference><Citation>Transcult Psychiatry. 2009 Mar;46(1):16-37</Citation><ArticleIdList><ArticleId IdType="pubmed">19293278</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Oncol (R Coll Radiol). 2013 Mar;25(3):178-89</Citation><ArticleIdList><ArticleId IdType="pubmed">23079099</ArticleId></ArticleIdList></Reference><Reference><Citation>Seizure. 2008 Oct;17(7):611-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18440245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Serv Res Policy. 2013 Oct;18(2 Suppl):38-49</Citation><ArticleIdList><ArticleId IdType="pubmed">24121835</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Expect. 2015 Dec;18(6):2693-703</Citation><ArticleIdList><ArticleId IdType="pubmed">25059530</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 May;57(5):648-59</Citation><ArticleIdList><ArticleId IdType="pubmed">16675759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Dec;15(8):865-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24119180</ArticleId></ArticleIdList></Reference><Reference><Citation>Accid Emerg Nurs. 2007 Oct;15(4):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18042484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29179014</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>260</Volume><PubDate><Year>2018</Year><Month>02</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Clinical utility of biomarkers of the hand in the diagnosis of schizophrenia.</ArticleTitle><Pagination><MedlinePgn>105-110</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31306-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2017.11.049</ELocationID><Abstract><AbstractText>A number of biomarkers were assessed in photos and prints of the hands of 95 patients with a variety of mental disorders to determine whether patients with schizophrenia could be distinguished from the others. Patients were recruited as consecutive admissions from an outpatient psychiatric day hospital population. Fourteen patients were diagnosed with schizophrenia/schizoaffective disorder and 81 were diagnosed with other mental disorders. A discriminant analysis yielded an overall 80% correct classification, with a sensitivity (schizophrenia patients identified correctly) of 78.6% and a specificity (non-schizophrenia patients identified correctly) of 80.2%. Significant differences were noted in the proximal interphalangeal joint, eponychium of the middle digit and fingernails. To determine biomarker frequency distribution patients with bipolar disorder were then compared to those with schizophrenia/schizoaffective disorder and then to patients with PTSD. The former yielded an overall 78.6% correct classification, with a sensitivity of 71.4% and a specificity of 85.7% and with similar biomarker frequency distribution for bipolar disorder as for the entire non schizophrenia group. The latter comparison yielded an overall 58.6% correct classification, with no significant differences between the features. The application of these biomarkers in clinical practice could constitute an additional tool for the psychiatrist in cases lacking diagnostic clarity.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Domany</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Abarbanel Mental Health Center, Psychiatric Day Hospital, Bat-Yam, Israel. Electronic address: anatzakran@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassan</LastName><ForeName>Stanley Morris</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarrasch</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Education, Tel Aviv University, Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lifshitz</LastName><ForeName>Tova</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Abarbanel Mental Health Center, Psychiatric Day Hospital, Bat-Yam, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Shaul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamir</LastName><ForeName>Eyal Zvi</ForeName><Initials>EZ</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Abarbanel Mental Health Center, Psychiatric Day Hospital, Bat-Yam, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006225" MajorTopicYN="N">Hand</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Biological markers</Keyword><Keyword MajorTopicYN="Y">Bipolar</Keyword><Keyword MajorTopicYN="Y">Dermatoglyphics</Keyword><Keyword MajorTopicYN="Y">Minor physical anomalies</Keyword><Keyword MajorTopicYN="Y">Post Traumatic Stress Disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29179014</ArticleId><ArticleId IdType="pii">S0165-1781(17)31306-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2017.11.049</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23881708</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Activated depression: mixed bipolar disorder or agitated unipolar depression?</ArticleTitle><Pagination><MedlinePgn>376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-013-0376-1</ELocationID><Abstract><AbstractText>The combination of depression and activation presents clinical and diagnostic challenges. It can occur, in either bipolar disorder or major depressive disorder, as increased agitation as a dimension of depression. What is called agitation can consist of expressions of painful inner tension or as disinhibited goal-directed behavior and thought. In bipolar disorder, elements of depression can be combined with those of mania. In this case, the agitation, in addition to increased motor activity and painful inner tension, must include symptoms of mania that are related to goal-directed behavior or manic cognition. These diagnostic considerations are important, as activated depression potentially carries increased behavioral risk, especially for suicidal behavior, and optimal treatments for depressive episodes differ between bipolar disorder and major depressive disorder. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>Alan C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, 1941 East Road, Room 3216, Houston, TX 77054, USA. alan.c.swann@uth.tmc.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23881708</ArticleId><ArticleId IdType="doi">10.1007/s11920-013-0376-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 2011 Dec 30;190(2-3):212-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21663976</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2006;23(7):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16823857</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Mar;123(3):206-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20825373</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1680-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16135628</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Apr;91(2-3):133-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16458364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Apr;27(4):255-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8509526</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Mar;42(3):288-94</Citation><ArticleIdList><ArticleId IdType="pubmed">3977548</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(433):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17280571</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2005;6(3):198-205</Citation><ArticleIdList><ArticleId IdType="pubmed">16166029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Apr;85(3):245-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15780694</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Apr;34(4):470-7</Citation><ArticleIdList><ArticleId IdType="pubmed">192169</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2001;32(1 Suppl):49-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11924695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11869757</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 May 15;35(10):803-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7519061</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2007;40(3):153-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17318007</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15146335</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Apr;85(4):270-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1595360</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2004 Apr;5(2):107-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15179670</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):31-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23223893</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18806921</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Jan;168(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21078709</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacol Hung. 2008 Mar;10(1):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18771019</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Nov;157:723-34</Citation><ArticleIdList><ArticleId IdType="pubmed">1980627</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Apr;44(4):345-54</Citation><ArticleIdList><ArticleId IdType="pubmed">2436590</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2009;10(3):196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19396703</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2008;41(3):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18337629</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2011 Apr;65(3):286-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21507136</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Oct 15;120(3):273-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14561439</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1348-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17728419</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 Nov-Dec;46(6):399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">16275206</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2005 Oct;59(5):570-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16194260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May 15;148(1):129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23219059</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15588754</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Nov;142(11):1291-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4061688</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1972 Sep;27(3):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4340658</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1992 Jun;25(2):97-105</Citation><ArticleIdList><ArticleId IdType="pubmed">1644992</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 May;37(2):195-205</Citation><ArticleIdList><ArticleId IdType="pubmed">1876629</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Mar-Apr;44(2):110-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12658619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Feb;84(2-3):133-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15708410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 May;138(3):440-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22314261</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 1984 Oct;55(2):619-71</Citation><ArticleIdList><ArticleId IdType="pubmed">6514929</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2007;76(6):325-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17917467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nord J Psychiatry. 2011 Dec;65(6):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21728783</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 Mar;41(3):257-67</Citation><ArticleIdList><ArticleId IdType="pubmed">6367690</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 May 30;197(3):231-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22357357</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2005;7(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15841189</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 May 15;207(1-2):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23433872</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1043-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16682104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jan;73(1):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22316575</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Jan;120(1-3):16-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19735945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 May;67(5):712-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16841620</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Jan 1;37(1):60-2</Citation><ArticleIdList><ArticleId IdType="pubmed">7893862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 May;9(3):206-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17430294</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):86-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18992784</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2001 May-Jun;42(3):196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">11349237</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Feb;166(2):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19122008</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2009 Oct;8(3):166-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19812754</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Apr 15;45(8):979-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10386180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Mar;15(2):223-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23286455</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 May;46(5):616-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22326294</ArticleId></ArticleIdList></Reference><Reference><Citation>Nord J Psychiatry. 2008;62(2):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18569776</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2008 Jan;23(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17764909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Jan;136(1-2):e41-e49</Citation><ArticleIdList><ArticleId IdType="pubmed">20129674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1994 Jul-Aug;28(4):357-67</Citation><ArticleIdList><ArticleId IdType="pubmed">7877115</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Jun;28(2):81-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8354772</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1982 Feb;12(1):25-36</Citation><ArticleIdList><ArticleId IdType="pubmed">7079431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27395460</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1881-6096</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain and nerve = Shinkei kenkyu no shinpo</Title><ISOAbbreviation>Brain Nerve</ISOAbbreviation></Journal><ArticleTitle>[Depression and Bipolar Disorder: Risk Factors and Potential Prevention of Developing Dementia].</ArticleTitle><Pagination><MedlinePgn>753-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11477/mf.1416200507</ELocationID><Abstract><AbstractText>Epidemiological studies have demonstrated that suffering from depression and bipolar disorder may be risk factors for developing dementia. A mechanism of interactions of several factors, such as vascular disease and glucocorticoid, has been speculated to play a role in the development of dementia. It is suggested that the onset of dementia can be prevented or delayed by preventing the onset and recurrence of depression and bipolar disorder. In the prevent of depression, the management of daily life, such as diet and exercise, is important. Recently, the possibility of preventive effects of antidepressants and lithium on developing dementia has been suggested, and a future intervention study is expected. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Science, Juntendo Graduate School of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Brain Nerve</MedlineTA><NlmUniqueID>101299709</NlmUniqueID><ISSNLinking>1881-6096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27395460</ArticleId><ArticleId IdType="pii">1416200507</ArticleId><ArticleId IdType="doi">10.11477/mf.1416200507</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6718599</PMID><DateCompleted><Year>1984</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>1984</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[Report of experiences with high dosage Hydiphen infusion treatment of depressive syndromes].</ArticleTitle><Pagination><MedlinePgn>95-100</MedlinePgn></Pagination><Abstract><AbstractText>25 patients with therapy-resistant depressive syndromes of various origins were treated by the infusion of high Hydiphen doses, a very effective thymoleptic drug with no dissociation between its drive increasing and spirit raising actions. The results yielded by this treatment varied from good to very good in respect of endogenic depressions, in which the mood was observed to change at doses between 150 and 425 mg/d, depending on the severity of the depression. The results of this treatment were less satisfactory in the case of reactive and bran-organically induced depressions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dreves</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Manthey</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Schmieter</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Haiduk</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Erfahrungsbericht über hochdosierte Hydiphen-Infusionsbehandlung bei depressiven Syndromen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>NUV44L116D</RegistryNumber><NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002997" MajorTopicYN="N">Clomipramine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007263" MajorTopicYN="N">Infusions, Parenteral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6718599</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17854257</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 1: challenges and developments.</ArticleTitle><Pagination><MedlinePgn>1301-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Correll</LastName><ForeName>Christoph U</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>The Zucker Hillside Hospital, Glen Oaks.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="N">Polypharmacy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>26</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17854257</ArticleId><ArticleId IdType="doi">10.4088/jcp.v68n0819</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2643052</PMID><DateCompleted><Year>1989</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>320</Volume><Issue>5</Issue><PubDate><Year>1989</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Clonazepam in the treatment of steroid-induced mania in a patient after renal transplantation.</ArticleTitle><Pagination><MedlinePgn>319-20</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Glickman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2643052</ArticleId><ArticleId IdType="doi">10.1056/NEJM198902023200517</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">23157799</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Sleep, psychiatric disorders and suicide.</ArticleTitle><Pagination><MedlinePgn>135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2012.09.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(12)00281-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>J John</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Oquendo</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH090964</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Psychiatr Res. 2012 Oct;46(10):1267-71</RefSource><PMID Version="1">22858352</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>J Psychiatr Res. 2013 Jan;47(1):133-4</RefSource><PMID Version="1">23157798</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23157799</ArticleId><ArticleId IdType="pii">S0022-3956(12)00281-6</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2012.09.011</ArticleId><ArticleId IdType="pmc">PMC3810958</ArticleId><ArticleId IdType="mid">NIHMS511184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 2003 Jul 15;119(1-2):33-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12860358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2001 Jun;13(2):93-101</Citation><ArticleIdList><ArticleId IdType="pubmed">11534931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Feb;136(3):743-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22032872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Sep;133(1-2):239-46</Citation><ArticleIdList><ArticleId IdType="pubmed">21546092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 Oct;46(10):1267-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22858352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27469479</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8042</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Pharmacogenomics</Title><ISOAbbreviation>Pharmacogenomics</ISOAbbreviation></Journal><ArticleTitle>Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6.</ArticleTitle><Pagination><MedlinePgn>1291-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs-2016-0105</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sánchez-Martín</LastName><ForeName>Almudena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University Hospital of Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sánchez-Iglesias</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital of Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Berrocal</LastName><ForeName>Belén</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, University Hospital of Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital of Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaedigk</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Toxicology &amp; Therapeutic Innovation, Children's Mercy Hospital, Kansas City, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isidoro-García</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, University Hospital of Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Salamanca, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacogenomics</MedlineTA><NlmUniqueID>100897350</NlmUniqueID><ISSNLinking>1462-2416</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D019389">Cytochrome P-450 CYP2D6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019389" MajorTopicYN="N">Cytochrome P-450 CYP2D6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">CYP2D6</Keyword><Keyword MajorTopicYN="Y">adverse event</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">pharmacogenetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27469479</ArticleId><ArticleId IdType="doi">10.2217/pgs-2016-0105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16157163</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Creativity in familial bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>623-31</MedlinePgn></Pagination><Abstract><AbstractText>Studies have demonstrated relationships between creativity and bipolar disorder (BD) in individuals, and suggested familial transmission of both creativity and BD. However, to date, there have been no studies specifically examining creativity in offspring of bipolar parents and clarifying mechanisms of intergenerational transmission of creativity. We compared creativity in bipolar parents and their offspring with BD and bipolar offspring with attention-deficit/hyperactivity disorder (ADHD) with healthy control adults and their children. 40 adults with BD, 20 bipolar offspring with BD, 20 bipolar offspring with ADHD, and 18 healthy control parents and their healthy control children completed the Barron-Welsh Art Scale (BWAS), an objective measure of creativity. Adults with BD compared to controls scored significantly (120%) higher on the BWAS Dislike subscale, and non-significantly (32%) higher on the BWAS Total scale. Mean BWAS Dislike subscale scores were also significantly higher in offspring with BD (107% higher) and offspring with ADHD (91% higher) than in healthy control children. Compared to healthy control children, offspring with BD had 67% higher and offspring with ADHD had 40% higher BWAS Total scores, but these differences failed to reach statistical significance when adjusted for age. In the bipolar offspring with BD, BWAS Total scores were negatively correlated with duration of illness. The results of this study support an association between BD and creativity and contribute to a better understanding of possible mechanisms of transmission of creativity in families with genetic susceptibility for BD. This is the first study to show that children with and at high risk for BD have higher creativity than healthy control children. The finding in children and in adults was related to an enhanced ability to experience and express dislike of simple and symmetric images. This could reflect increased access to negative affect, which could yield both benefits with respect to providing affective energy for creative achievement, but also yield liabilities with respect to quality of interpersonal relationships or susceptibility to depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simeonova</LastName><ForeName>Diana I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Stanford University School of Medicine, Stanford, CA 94305 5540, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Strong</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH64460-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="Y">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="N">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16157163</ArticleId><ArticleId IdType="pii">S0022-3956(05)00009-9</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2005.01.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20807972</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><Volume>197</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Group-based psychosocial intervention for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>246; author reply 246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.197.3.246</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sumeet</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Br J Psychiatry. 2010 May;196(5):383-8</RefSource><PMID Version="1">20435965</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="Y">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20807972</ArticleId><ArticleId IdType="pii">S0007125000015828</ArticleId><ArticleId IdType="doi">10.1192/bjp.197.3.246</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28506924</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7528</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neuroscience and biobehavioral reviews</Title><ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation></Journal><ArticleTitle>Olfactory and gustatory functions in bipolar disorders: A systematic review.</ArticleTitle><Pagination><MedlinePgn>69-79</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0149-7634(17)30235-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2017.05.009</ELocationID><Abstract><AbstractText>Olfactory and gustatory dysfunctions have been described in different psychiatric disorders. Several studies have found gustatory and olfactory function change in bipolar disorders with various results. The aim of this study is to have a systematic review of studies evaluating gustatory and olfactory function in bipolar disorders. After a systematic search, 15 studies on olfaction and 5 studies on taste were included in this review. The UPSIT (University of Pennsylvania Smell Identification Test) and Sniffin' Sticks were the most widely used tests to evaluate smell. Some studies on olfaction described dysfunctions in smell identification as potential markers for bipolar disorders. Moreover, olfactory acuity was associated with psychosocial and cognitive performances. For taste, only few studies used standardized tests to evaluate gustation. These studies showed that patients with Bipolar disorders had more gustatory dysfunction compared to controls, and to non-bipolar depressed patients.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kazour</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM U930, équipe 4 "Troubles affectifs", Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France; Psychiatric Hospital of the Cross, 60096, Jal El Dib, Lebanon; Department of Psychiatry, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon. Electronic address: francoiskazour@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richa</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desmidt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>INSERM U930, équipe 4 "Troubles affectifs", Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France; Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaire</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U930, équipe 4 "Troubles affectifs", Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France; Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atanasova</LastName><ForeName>Boriana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM U930, équipe 4 "Troubles affectifs", Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Hage</LastName><ForeName>Wissam</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>INSERM U930, équipe 4 "Troubles affectifs", Université François-Rabelais de Tours, Parc de Grandmont, 37200 Tours, France; Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosci Biobehav Rev</MedlineTA><NlmUniqueID>7806090</NlmUniqueID><ISSNLinking>0149-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055697" MajorTopicYN="Y">Taste Perception</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Marker</Keyword><Keyword MajorTopicYN="N">Olfaction</Keyword><Keyword MajorTopicYN="N">Taste</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28506924</ArticleId><ArticleId IdType="pii">S0149-7634(17)30235-X</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2017.05.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15802085</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>How to differentiate bipolar disorder from attention deficit hyperactivity disorder and other common psychiatric disorders: a guide for clinicians.</ArticleTitle><Pagination><MedlinePgn>98-103</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder in children often is confused with attention deficit disorder, substance-induced mood disorder, oppositional defiant disorder, and conduct disorder. It is not uncommon for some of these disorders to be comorbid with pediatric bipolar disorder. This article provides the reader with a review of the existing literature on differentiating these illnesses and recognizing the phenomenology of each disorder as it pertains to a psychiatric diagnostic work-up of a child. Clinically helpful overlapping and unique characteristics of each disorder are discussed and a practical approach to differentiate these disorders is provided.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sood</LastName><ForeName>Aradhana Bela</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Virginia Commonwealth University Health Systems, 515 North 10th Street, Richmond, VA 23298, USA. bsood@hsc.vcu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razdan</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Elizabeth B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Ronald A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019955" MajorTopicYN="N">Conduct Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>45</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15802085</ArticleId><ArticleId IdType="doi">10.1007/s11920-005-0005-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adolescence. 1990 Winter;25(100):855-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2275442</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Mar 15;39(6):458-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8679794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7608044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):941-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9204672</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jan;157(1):130-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10618028</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Nerv Syst. 1977 Jun;38(6):480-3</Citation><ArticleIdList><ArticleId IdType="pubmed">862509</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 1995 Feb;37(2):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7758404</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Feb;152(2):271-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7840364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1996 Jun;(30):58-67</Citation><ArticleIdList><ArticleId IdType="pubmed">8864150</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):365-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7864261</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Dec;152(12):1793-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8526248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1494-503</Citation><ArticleIdList><ArticleId IdType="pubmed">14627885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Dec;56(12):1073-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10591283</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15123490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Sep;34(9):1221-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7559318</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Mar;157(3):466-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10698829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001;62 Suppl 14:10-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11469669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7649957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Mar;31(2):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1564026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1995 May;68(5):901-16</Citation><ArticleIdList><ArticleId IdType="pubmed">7776186</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 Feb;145(2):221-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3124634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1995 Aug 18;34(4):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">8550951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):330-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525553</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1991;240(6):339-48</Citation><ArticleIdList><ArticleId IdType="pubmed">1831665</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Dev. 1984 Winter;2(4):273-85</Citation><ArticleIdList><ArticleId IdType="pubmed">6441929</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Oct;64(10):1170-6; quiz, 1274-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14658964</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1979 May;136(5):702-6</Citation><ArticleIdList><ArticleId IdType="pubmed">434252</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Jun 15;49(12):1062-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11430848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008</Citation><ArticleIdList><ArticleId IdType="pubmed">8755796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):21-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9000777</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1986 Jun;43(6):577-82</Citation><ArticleIdList><ArticleId IdType="pubmed">3707290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1999 Jun;38(6):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10361785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Nerv Syst. 1975 Apr;36(4):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1116423</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1989 Aug;34(6):526-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2766205</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Mar;78(3):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15013241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Dec;34(12):1577-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8543528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 1999;9(4):247-56</Citation><ArticleIdList><ArticleId IdType="pubmed">10630454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12014593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15013827</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>588-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a previous investigation, we found an association between reduced cognitive functioning and the prevalence of antibodies to herpes simplex virus type 1 in individuals with schizophrenia. The current study was undertaken to determine if this association also occurs in individuals with bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cognitive functioning and serologic evidence of infection with potentially neurotropic herpesviruses were measured in 117 individuals with bipolar disorder and in 100 individuals without a history of psychiatric disorder. Cognitive functioning was evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status. For each patient, serologic evidence of infection was ascertained by the measurement of serum immunoglobulin G class antibodies with specificities for six potentially neurotropic human herpesviruses. The association between serologic evidence of herpesvirus infection and cognitive functioning was analyzed by univariate analyses, as well as multivariate analyses that included demographic and clinical factors associated with cognitive functioning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serologic evidence of infection with herpes simplex virus type 1 was an independent predictor of decreased cognitive functioning in the individuals with bipolar disorder (F = 20.5, p &lt;.0001). Discriminant function analysis indicated that most of the difference in cognitive functioning between individuals who were antibody positive and antibody negative for herpes simplex virus type 1 could be attributed to immediate verbal memory (F = 12.07, p &lt;.001). There was no significant association between cognitive functioning and the other human herpesviruses. No association between antibodies to herpesviruses and cognitive functioning was found in the control individuals without a history of psychiatric disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serologic evidence of herpes simplex virus type 1 infection is associated with cognitive impairment in individuals with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Faith B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Stanley Research Center, Sheppard Pratt Health System, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boronow</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Stallings</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Origoni</LastName><ForeName>Andrea E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Krivogorsky</LastName><ForeName>Bogdana</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yolken</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="N">Herpesviridae Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="Y">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15013827</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2003.10.008</ArticleId><ArticleId IdType="pii">S0006322303010965</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26394555</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study.</ArticleTitle><Pagination><MedlinePgn>705-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12336</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The risk of stroke is increased in patients with bipolar disorder. Lithium exhibits neuroprotective effects but the association between lithium use and the risk of stroke is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A population-based retrospective cohort study was conducted by utilizing the National Health Insurance Research Database in Taiwan. Subjects who had first been diagnosed with bipolar disorder between 2001 and 2006 were identified. A propensity score (PS) for receiving lithium was calculated with variables of age, gender, and comorbidities. The patients with bipolar disorder receiving lithium within the period from diagnosis through to December 2011 were designated as the lithium group (n = 635). A 1:2 ratio was used to select PS-matched subjects with bipolar disorder without lithium use (n = 1,250). Multivariate Cox proportional hazards regression models were used to explore the association, rather than causal inference, of lithium exposure and the risk of stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1,885 subjects, 86 (4.6%) experienced stroke, including 2.8% of the lithium group and 5.4% of the non-lithium group. Lithium use was associated with a significantly reduced risk of stroke [hazard ratio (HR) = 0.39, 95% confidence interval (CI): 0.22-0.68]. Reduced risks of stroke were also associated with the highest cumulative lithium dose [≥720 defined daily dose (DDD), HR = 0.25, 95% CI: 0.10-0.59], the longest cumulative exposure period (≥720 days, HR = 0.20, 95% CI: 0.06-0.64), and the highest exposure rate (≥2 DDD/day, HR = 0.39, 95% CI: 0.21-0.70).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lithium use was significantly related to a reduced risk of stroke in patients with bipolar disorder.</AbstractText><CopyrightInformation>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Chen-Chia</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, Taipei Municipal Gan-Dau Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chien</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Yang-Ming University Hospital, Yilan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ching-Heng</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Tzuo-Yun</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Institute of Hospital Management, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>Melvin G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Chin-Hong</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Tsuo-Hung</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">lithium</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">risk</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26394555</ArticleId><ArticleId IdType="doi">10.1111/bdi.12336</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3813808</PMID><DateCompleted><Year>1987</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>1987</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Schizoaffective psychosis. II. Manic, bipolar, and depressive subtypes.</ArticleTitle><Pagination><MedlinePgn>138-9</MedlinePgn></Pagination><Abstract><AbstractText>Three schizoaffective subtypes-manic, bipolar, and depressive-were compared across multiple baseline (demographic, premorbid, morbid) and long-term outcome dimensions. Though the subtypes were comparable at baseline, the patients with depressive schizoaffective disorder scored consistently better at follow-up, although none of these differences was statistically significant. Results failed to support the validity of such subtyping in schizoaffective disorder, at least in predominantly chronic populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGlashan</LastName><ForeName>T H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>P V</ForeName><Initials>PV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH35174-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="N">Manuals as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3813808</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1987.01800140040006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10898915</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0148-7299</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>American journal of medical genetics</Title><ISOAbbreviation>Am J Med Genet</ISOAbbreviation></Journal><ArticleTitle>5-HT2a receptor polymorphism gene in bipolar disorder and harm avoidance personality trait.</ArticleTitle><Pagination><MedlinePgn>360-4</MedlinePgn></Pagination><Abstract><AbstractText>The purpose [corrected] of this study was to investigate the relationship between bipolar disorder and the harm avoidance personality trait (HA), and the genetic contribution of the polymorphic DNA variation T102C in exon 1 of 5-HTR2a (chromosome 13q14-21) in bipolar disorder and HA personality trait. Forty bipolar patients and 89 normal subjects completed the TPQ questionnaire and were genotyped for 5-HT2a. Bipolar patients scored higher than normal subjects on the HA dimension. However, no contribution of the 5-HTR2a polymorphism on the bipolar disorder or on the HA personality trait emerged. Despite the limited sample size, these results exclude a major effect of the 5-HTR2a polymorphism on bipolar disorder and HA personality trait but not a minor effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blairy</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Free University of Brussels, Erasme Hospital, Belgium. sblairy@ulb.ac.be</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massat</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Staner</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Le Bon</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Van Gestel</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hilger</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hentges</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Souery</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet</MedlineTA><NlmUniqueID>7708900</NlmUniqueID><ISSNLinking>0148-7299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="N">Chromosome Aberrations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025063" MajorTopicYN="N">Chromosome Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002882" MajorTopicYN="N">Chromosomes, Human, Pair 13</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10898915</ArticleId><ArticleId IdType="pii">10.1002/1096-8628(20000612)96:3&lt;360::AID-AJMG24&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="doi">10.1002/1096-8628(20000612)96:3&lt;360::aid-ajmg24&gt;3.0.co;2-e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9016284</PMID><DateCompleted><Year>1997</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>2</Issue><PubDate><Year>1997</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Treatment of acute mania with gabapentin.</ArticleTitle><Pagination><MedlinePgn>287</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>P E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="Y">Amines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="Y">Cyclohexanecarboxylic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="Y">gamma-Aminobutyric Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9016284</ArticleId><ArticleId IdType="doi">10.1176/ajp.154.2.287a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15708427</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>84</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the "red sign," the "rule of three" and other biographic signs of temperamental extravagance, activation and hypomania.</ArticleTitle><Pagination><MedlinePgn>279-90</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since 1977, the work of the author has shown the primacy of behavioral activation, flamboyance, and extravagance in detecting hypomania, the historical hallmark of cyclothymic and the broader spectrum of bipolar II (BP-II) disorders. In other words, the soft spectrum is more likely to declare itself in behavioral rather than mood disturbances. The obligatory search for elation and related mood changes a la DSM-IV (and its interview form, the SCID) during the clinical interview is often doomed to failure, thereby "condemning" the patient to a unipolar diagnosis, and hence to sequential and often tragic failures with antidepressants or combinations thereof.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To characterize behavioral signs of good specificity, though individually of low sensitivity for BP-II in patents presenting with major depression, the author undertook a chart review of over 1000 depressive patients he had examined extending over a period of nearly three decades. The Mood Clinic Data Questionnaire (MCDQ) used in the author's Memphis mood clinic permitted systematization of unstructured observations. BP-II had been independently confirmed by hypomania of &gt; or =2 days and/or cyclothymia over the course of the index illness (both of which were validated by family history for bipolarity in earlier research in our clinic).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Triads of behavior or traits in the patients' biographical history-as well as in the biologic kin-involving polyglottism, eminence, creative achievement, professional instability, multiple substance/alcohol use, multiple comorbidity (axis I and axis II), multiple marriages, a broad repertoire of sexual behavior (including brief interludes of homosexuality), impulse control disorders, as well as ornamentation and flamboyance (with red and other bright colors dominating) were specific for BP-II. Temperamentally, many of these individuals thrive on activity-they are indeed "activity junkies."</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">The reported findings pertain primarily to the differential diagnosis between BP-II and unipolar depression. Replication of the approach espoused herein will require quantification of the operational definitions of the observed phenomenology.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings, which make sense in an evolutionary model of the advantage that "dilute" bipolar traits confer to human biography and erotic life, suggest that such behavioral traits can be useful provisionally in assigning a depressive episode to the realm of the bipolar II spectrum. Overall, the perspective espoused in this paper indicates that temperamental excesses and, more generally, a biographical approach, represent a more coherent approach than hypomanic episodes in the diagnosis of BP-II patients. Finally, such a diagnostic approach underscores the importance of incorporating evolutionary considerations and principles in understanding the origin of affective disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California at San Diego, V.A. Hospital 3350, La Jolla Village Dr. (116-A), San Diego CA 92161, USA. hakiskal@ucsd.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="Y">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005010" MajorTopicYN="N">Ethology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="Y">Euphoria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019303" MajorTopicYN="N">Multilingualism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>01</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15708427</ArticleId><ArticleId IdType="pii">S0165-0327(04)00183-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.06.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19443616</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.</ArticleTitle><Pagination><MedlinePgn>73-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbp034</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Neurocognitive dysfunction is milder in bipolar disorders than in schizophrenia spectrum disorders, supporting a dimensional approach to severe mental disorders. The aim of this study was to investigate the role of lifetime history of psychosis for neurocognitive functioning across these disorders. We asked whether neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends more on history of psychosis than diagnostic category or subtype.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A sample of individuals with schizophrenia (n=102), schizoaffective disorder (n=27), and bipolar disorder (I or II) with history of psychosis (n=75) and without history of psychosis (n=61) and healthy controls (n=280), from a large ongoing study on severe mental disorder, were included. Neurocognitive function was measured with a comprehensive neuropsychological test battery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with controls, all 3 groups with a history of psychosis performed poorer across neurocognitive measures, while the bipolar group without a history of psychosis was only impaired on a measure of processing speed. The groups with a history of psychosis did not differ from each other but performed poorer than the group without a history of psychosis on a number of neurocognitive measures. These neurocognitive group differences were of a magnitude expected to have clinical significance. In the bipolar sample, history of psychosis explained more of the neurocognitive variance than bipolar diagnostic subtype.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders is determined more by history of psychosis than by Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) diagnostic category or subtype, supporting a more dimensional approach in future diagnostic systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simonsen</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, 0317 Oslo, Norway. c.e.simonsen@medisin.uio.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundet</LastName><ForeName>Kjetil</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vaskinn</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Birkenaes</LastName><ForeName>Astrid B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Engh</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Faerden</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jónsdóttir</LastName><ForeName>Halldóra</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ringen</LastName><ForeName>Petter Andreas</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Opjordsmoen</LastName><ForeName>Stein</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Friis</LastName><ForeName>Svein</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19443616</ArticleId><ArticleId IdType="pii">sbp034</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbp034</ArticleId><ArticleId IdType="pmc">PMC3004191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harv Rev Psychiatry. 2006 Mar-Apr;14(2):47-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16603472</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):532-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17485605</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1996 May;26(3):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8733206</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 1995;36 Suppl 2:S46-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8784214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Nov;60(3):147-57</Citation><ArticleIdList><ArticleId IdType="pubmed">11074103</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 14;272(22):1749-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7966923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Nov-Dec;37(6):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">14563379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16542181</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):286-93</Citation><ArticleIdList><ArticleId IdType="pubmed">14754778</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Dec;60(12):874-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10665641</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 Jan;33(1):49-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17101692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Jan;186:32-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15630121</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Jan;107(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18786811</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Jun;64(6):633-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17548746</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Sep;118(3):172-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18699952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18232725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Jul;36(4):830-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19176474</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 15;55(10):1013-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15121486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):245-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18271903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Feb;99(1-3):149-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18031992</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2008 Jan;23(1):20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18083013</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Jul-Aug;44(4):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12923703</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1988 Jun;8(3):207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">3379146</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Dec 15;80(2-3):137-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16183257</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1979 Mar;86(2):420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18839484</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Mar 15;57(6):633-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15780850</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2001 Mar-Apr;35(2):119-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11377441</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Dec;116(6):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17997724</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2007 Jun;6(2):84-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18235858</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2006;75(2):72-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16508342</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Sep;38(9):1241-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18070373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16762369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 Jul;33(4):886-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17562693</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Sep;189:254-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16946361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29179576</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>04</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.</ArticleTitle><Pagination><MedlinePgn>343-350</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2017.17020223</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The authors investigated the rates of conversion to schizophrenia and bipolar disorder after a substance-induced psychosis, as well as risk factors for conversion.</AbstractText><AbstractText Label="METHOD">All patient information was extracted from the Danish Civil Registration System and the Psychiatric Central Research Register. The study population included all persons who received a diagnosis of substance-induced psychosis between 1994 and 2014 (N=6,788); patients were followed until first occurrence of schizophrenia or bipolar disorder or until death, emigration, or August 2014. The Kaplan-Meier method was used to obtain cumulative probabilities for the conversion from a substance-induced psychosis to schizophrenia or bipolar disorder. Cox proportional hazards regression models were used to calculate hazard ratios for all covariates.</AbstractText><AbstractText Label="RESULTS">Overall, 32.2% (95% CI=29.7-34.9) of patients with a substance-induced psychosis converted to either bipolar or schizophrenia-spectrum disorders. The highest conversion rate was found for cannabis-induced psychosis, with 47.4% (95% CI=42.7-52.3) converting to either schizophrenia or bipolar disorder. Young age was associated with a higher risk of converting to schizophrenia. Self-harm after a substance-induced psychosis was significantly linked to a higher risk of converting to both schizophrenia and bipolar disorder. Half the cases of conversion to schizophrenia occurred within 3.1 years after a substance-induced psychosis, and half the cases of conversion to bipolar disorder occurred within 4.4 years.</AbstractText><AbstractText Label="CONCLUSIONS">Substance-induced psychosis is strongly associated with the development of severe mental illness, and a long follow-up period is needed to identify the majority of cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Starzer</LastName><ForeName>Marie Stefanie Kejser</ForeName><Initials>MSK</Initials><AffiliationInfo><Affiliation>From Mental Health Center Copenhagen, Copenhagen University Hospital; and the Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen and Aarhus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordentoft</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Mental Health Center Copenhagen, Copenhagen University Hospital; and the Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen and Aarhus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjorthøj</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Mental Health Center Copenhagen, Copenhagen University Hospital; and the Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen and Aarhus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2018 Apr 1;175(4):303-304</RefSource><PMID Version="1">29606066</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Psychiatry. 2019 Apr 1;176(4):324</RefSource><PMID Version="1">30929503</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002188" MajorTopicYN="N">Cannabis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Alcohol Abuse</Keyword><Keyword MajorTopicYN="Y">Mood Disorders-Bipolar</Keyword><Keyword MajorTopicYN="Y">Psychoactive Substance Use Disorder</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29179576</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2017.17020223</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8434691</PMID><DateCompleted><Year>1993</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9564</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Season>Winter</Season></PubDate></JournalIssue><Title>American journal of psychotherapy</Title><ISOAbbreviation>Am J Psychother</ISOAbbreviation></Journal><ArticleTitle>Living with mania: a study of outpatient group psychotherapy for bipolar patients.</ArticleTitle><Pagination><MedlinePgn>113-26</MedlinePgn></Pagination><Abstract><AbstractText>This article describes an outpatient group psychotherapy with fourteen bipolar patients. Contrary to previous pessimistic reports in the literature, the author demonstrates that group therapy with these patients is both feasible and beneficial, and that it contributes to an ameloriation of the natural course of this illness. Group psychotherapy, with its enhancement of medication compliance, effective challenge of denial mechanisms, and facilitation of increased awareness of internal and external stressors, can thus be an effective tool in the therapeutic armamentarium against the ravages of bipolar illness. Significant themes arising in the group, common defensive operations, and therapeutic techniques are discussed. In addition, phases of recovery and group development are reviewed in the context of relevant interventions. Treating bipolars in group therapy is a fascinating and rewarding experience, full of potential gains in understanding and influencing the course of this complicated illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Bethesda PsycHealth System, Denver, CO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychother</MedlineTA><NlmUniqueID>0110672</NlmUniqueID><ISSNLinking>0002-9564</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="Y">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8434691</ArticleId><ArticleId IdType="doi">10.1176/appi.psychotherapy.1993.47.1.113</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25297388</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Level of plasma thioredoxin in male patients with manic episode at initial and post-electroconvulsive or antipsychotic treatment.</ArticleTitle><Pagination><MedlinePgn>344-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12244</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Oxidative stress is defined as exposure to excessive oxidants and/or decrease in antioxidant capacity. Several studies have shown the effects of free radicals and antioxidant defense systems in bipolar disorder. We aimed to investigate the role of thioredoxin (TRX), which is a novel oxidative stress marker in patients with bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty-eight hospitalized bipolar patients who were in manic episode were included in the study. As a control group, 30 healthy people were elected. Two groups were formed. The first group consisted of patients who were undergoing electroconvulsive treatment + antipsychotic treatment (haloperidol+quetiapine) and members of the other group were taking only antipsychotic treatment. Plasma thioredoxin levels were measured before and after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pretreatment plasma TRX levels of patients were significantly lower than the controls (P &lt; 0.05). Comparing pre- and post-treatment plasma TRX levels of all patients, post-treatment plasma TRX levels were significantly lower than the pre-treatment plasma TRX levels (P &lt; 0.05). When we compared TRX levels between the electroconvulsive treatment + antipsychotic treatment group and the antipsychotic treatment group (P &gt; 0.05) and within groups (P &gt; 0.05) we did not find any statistically significant difference.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Oxidative balance is impaired in bipolar disorder manic episode in favor of the oxidants. Decreased plasma TRX levels in the manic episode probably mean that antioxidant capacity is decreased in the bipolar disorder patients in the manic episode. Further studies in euthymic and depressive states are also needed to gain more insight into the role of TRX in bipolar disorder.</AbstractText><CopyrightInformation>© 2014 The Authors. Psychiatry and Clinical Neurosciences © 2014 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Genc</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalelioglu</LastName><ForeName>Tevfik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamustafalioglu</LastName><ForeName>Nesrin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasdemir</LastName><ForeName>Akif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gungor</LastName><ForeName>Ferda Can</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genc</LastName><ForeName>Esra Sena</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Incir</LastName><ForeName>Said</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilnem</LastName><ForeName>Cem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emul</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>52500-60-4</RegistryNumber><NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">electroconvulsive therapy</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">thioredoxin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25297388</ArticleId><ArticleId IdType="doi">10.1111/pcn.12244</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29601896</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><PubDate><Year>2019</Year><Month>04</Month><Day>20</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Differentiating between bipolar and unipolar depression in functional and structural MRI studies.</ArticleTitle><Pagination><MedlinePgn>20-27</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(18)30051-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2018.03.022</ELocationID><Abstract><AbstractText>Distinguishing depression in bipolar disorder (BD) from unipolar depression (UD) solely based on clinical clues is difficult, which has led to the exploration of promising neural markers in neuroimaging measures for discriminating between BD depression and UD. In this article, we review structural and functional magnetic resonance imaging (MRI) studies that directly compare UD and BD depression based on neuroimaging modalities including functional MRI studies on regional brain activation or functional connectivity, structural MRI on gray or white matter morphology, and pattern classification analyses using a machine learning approach. Numerous studies have reported distinct functional and structural alterations in emotion- or reward-processing neural circuits between BD depression and UD. Different activation patterns in neural networks including the amygdala, anterior cingulate cortex (ACC), prefrontal cortex (PFC), and striatum during emotion-, reward-, or cognition-related tasks have been reported between BD and UD. A stronger functional connectivity pattern in BD was pronounced in default mode and in frontoparietal networks and brain regions including the PFC, ACC, parietal and temporal regions, and thalamus compared to UD. Gray matter volume differences in the ACC, hippocampus, amygdala, and dorsolateral prefrontal cortex (DLPFC) have been reported between BD and UD, along with a thinner DLPFC in BD compared to UD. BD showed reduced integrity in the anterior part of the corpus callosum and posterior cingulum compared to UD. Several studies performed pattern classification analysis using structural and functional MRI data to distinguish between UD and BD depression using a supervised machine learning approach, which yielded a moderate level of accuracy in classification.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kyu-Man</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Berardis</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Mental Health Psychiatric Service, Diagnosis and Treatment Hospital "G. Mazzini," ASL 4, NHS, Teramo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Head and Neck Department, Section of Psychiatry, University School of Medicine "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong-Ku</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea. Electronic address: yongku@korea.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069553" MajorTopicYN="N">Supervised Machine Learning</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar depression</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">functional imaging</Keyword><Keyword MajorTopicYN="Y">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="Y">major depressive disorder</Keyword><Keyword MajorTopicYN="Y">mood disorder</Keyword><Keyword MajorTopicYN="Y">structural imaging</Keyword><Keyword MajorTopicYN="Y">unipolar depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29601896</ArticleId><ArticleId IdType="pii">S0278-5846(18)30051-4</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2018.03.022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27066819</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association between childhood dimensions of attention deficit hyperactivity disorder and adulthood clinical severity of bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>382-392</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867416642021</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical features of attention deficit hyperactivity disorder can be frequently observed in cases with bipolar disorders and associated with greater severity of bipolar disorders. Although designed as a screening tool for attention deficit hyperactivity disorder, the Wender Utah Rating Scale could, given its factorial structure, be useful in investigating the early history of impulsive, inattentive or mood-related symptoms among patients with bipolar disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We rated the Wender Utah Rating Scale in 276 adult bipolar disorder cases and 228 healthy controls and tested its factorial structure and any associations with bipolar disorder phenomenology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We confirmed a three-factor structure for the Wender Utah Rating Scale (' impulsivity/temper', ' inattentiveness' and ' mood/self-esteem'). Cases and controls differed significantly on Wender Utah Rating Scale total score and sub-scale scores ( p-values &lt; 10<sup>-5</sup>). About 23% of bipolar disorder cases versus 5% of controls were classified as ' WURS positive' (odds ratio = 5.21 [2.73-9.95]). In bipolar disorders, higher Wender Utah Rating Scale score was associated with earlier age at onset, severity of suicidal behaviors and polysubstance misuse; multivariate analyses, controlling for age and gender, confirmed the associations with age at onset ( p = 0.001) and alcohol and substance misuse ( p = 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adults with bipolar disorders who reported higher levels of childhood symptoms on the Wender Utah Rating Scale presented a more severe expression of bipolar disorders in terms of age at onset and comorbidity. The Wender Utah Rating Scale could be employed to screen for attention deficit hyperactivity disorder but also for ' at-risk behaviors' in adult bipolar disorder cases and possibly for prodromal signs of early onset in high-risk subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1 Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 Inserm U955, Equipe Psychiatrie Translationnelle, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 AP-HP, Hôpitaux Universitaires Henri Mondor, DHU Pepsy, Pôle de Psychiatrie et d'Addictologie, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lajnef</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loftus</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>5 Centre Expert Trouble Bipolaire, Hospital Princesse Grace, Monaco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1 Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 Inserm U955, Equipe Psychiatrie Translationnelle, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 AP-HP, Hôpitaux Universitaires Henri Mondor, DHU Pepsy, Pôle de Psychiatrie et d'Addictologie, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raust</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3 AP-HP, Hôpitaux Universitaires Henri Mondor, DHU Pepsy, Pôle de Psychiatrie et d'Addictologie, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6 Service de Psychiatrie Adulte, Hôpital Charles Perrens Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>7 CHU de Nancy-Hôpitaux de Brabois, Service de Psychiatrie et Psychologie Clinique, Vandoeuvre Les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 Inserm U955, Equipe Psychiatrie Translationnelle, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 AP-HP, Hôpitaux Universitaires Henri Mondor, DHU Pepsy, Pôle de Psychiatrie et d'Addictologie, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>8 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>4 Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>9 AP-HP, GH Saint-Louis-Lariboisière-Fernand-Widal, Pôle Neurosciences, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10 Université Paris Diderot, UMR-S 1144, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">attention deficit</Keyword><Keyword MajorTopicYN="N">hyperactivity</Keyword><Keyword MajorTopicYN="N">impulsivity</Keyword><Keyword MajorTopicYN="N">misuse</Keyword><Keyword MajorTopicYN="N">onset</Keyword><Keyword MajorTopicYN="N">suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27066819</ArticleId><ArticleId IdType="pii">0004867416642021</ArticleId><ArticleId IdType="doi">10.1177/0004867416642021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8408977</PMID><DateCompleted><Year>1993</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>1993</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Childhood behavior problems and bipolar disorder--relationship or coincidence?</ArticleTitle><Pagination><MedlinePgn>143-53</MedlinePgn></Pagination><Abstract><AbstractText>A group of offspring at risk for Bipolar Disorder is compared to a Normal Control group whose parents had no psychiatric disorder and a group of offspring at risk for other, non-bipolar psychiatric disorder. Variables examined include childhood attention and behavior problems and psychopathology in young adulthood. Rates of childhood behavior and attention problems, and psychopathology and social/occupational impairment in young adulthood, were higher in the Bipolar Risk group than the Normal Control group, but no higher than in the non-bipolar (Combined Risk) group. Although childhood behavior and attention problems were significantly associated with other psychopathology in all three offspring groups, a unique relationship between childhood problems and young adult mood disorder was found only in the Bipolar Risk group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>G A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Child Psychiatry, State University of New York, Stony Brook.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8408977</ArticleId><ArticleId IdType="pii">0165-0327(93)90044-K</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(93)90100-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25362578</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8491</ISSN><JournalIssue CitedMedium="Internet"><Volume>265</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>83-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00406-014-0557-x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan, hashimoto@faculty.chiba-u.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C426674">brain-derived neurotrophic factor precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25362578</ArticleId><ArticleId IdType="doi">10.1007/s00406-014-0557-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2014 May;160:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24709015</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jul 1;54(1):70-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12842310</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(8):e42676</Citation><ArticleIdList><ArticleId IdType="pubmed">22880079</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2015 Feb;265(1):83-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25362578</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Mar 11;9(3):e91076</Citation><ArticleIdList><ArticleId IdType="pubmed">24618828</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2013 Jan;100:15-29</Citation><ArticleIdList><ArticleId IdType="pubmed">23044468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:330-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25012449</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2013 Dec;14(8):583-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22047184</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2004 May;45(2):104-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15145621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jul;19(7):791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">23958957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:193-200</Citation><ArticleIdList><ArticleId IdType="pubmed">25012431</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2010 Aug;64(4):341-57</Citation><ArticleIdList><ArticleId IdType="pubmed">20653908</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2014 May;71(5):653</Citation><ArticleIdList><ArticleId IdType="pubmed">24818682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21266890</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Improving treatment adherence in patients with bipolar disorder and substance abuse: rationale and initial development of a novel psychosocial approach.</ArticleTitle><Pagination><MedlinePgn>5-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/01.pra.0000393840.18099.d6</ELocationID><Abstract><AbstractText>Patients with comorbid bipolar and substance use disorders are at particularly high risk for treatment nonadherence and a host of negative consequences. However, no previous interventions have been designed specifically to address this problem. In the current study, we describe the rationale for and initial development of an adjunctive psychosocial intervention that targets adherence in patients with bipolar disorder who are substance abusers. The intervention involves brief in-person sessions and follow-up phone contacts with the patient and a significant other/family member. We describe the effects of this novel intervention on adherence and other psychiatric outcomes in a series of cases treated as part of our initial development work. Results suggest that the intervention is feasible and acceptable to patients and could be helpful in enhancing the effects of existing treatments. Given these promising results, we plan to test the intervention further in a randomized clinical trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaudiano</LastName><ForeName>Brandon A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Brown Medical School and Butler Hospital, Providence, RI 02906, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Ivan W</ForeName><Initials>IW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA023072</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA023072-01A1</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA023072</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012237" MajorTopicYN="N" Type="Geographic">Rhode Island</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21266890</ArticleId><ArticleId IdType="doi">10.1097/01.pra.0000393840.18099.d6</ArticleId><ArticleId IdType="pii">00131746-201101000-00002</ArticleId><ArticleId IdType="pmc">PMC3071706</ArticleId><ArticleId IdType="mid">NIHMS279356</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 2:63-9; discussion 75-6, 113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10073390</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 1993 Feb;16(2):434-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8432214</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Obes Metab. 2001 Feb;3(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11213594</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2003 Jun;26(2):381-409</Citation><ArticleIdList><ArticleId IdType="pubmed">12778840</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1986 Mar;148:279-87</Citation><ArticleIdList><ArticleId IdType="pubmed">3719220</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2009 Oct 1;104(3):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19573999</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jun;57(6):829-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16754760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Subst Abuse Treat. 2004 Dec;27(4):307-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15610832</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Feb 12;37(1):43-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8682977</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1980 Aug;112(2):185-99</Citation><ArticleIdList><ArticleId IdType="pubmed">6998287</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Addict. 1990 Sep;85(9):1177-85</Citation><ArticleIdList><ArticleId IdType="pubmed">2224198</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1991 Jun;59(3):439-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2071729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2003 Apr;253(4):430-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12653872</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12946886</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1998 Sep-Oct;6(3):133-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12519098</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1982 Jun 17;306(24):1437-40</Citation><ArticleIdList><ArticleId IdType="pubmed">6123079</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Apr;48(4):340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1672589</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1994 Jun;182(6):349-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8201307</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2006 Aug;74(4):671-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16881774</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Mar;30(2):467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10824667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Aug;3(4):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11552957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fla Med Assoc. 1979 Apr;66(4):482-8</Citation><ArticleIdList><ArticleId IdType="pubmed">430026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Apr;59(4):172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9590667</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1927-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12411230</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Behav. 1999 Jan-Feb;24(1):17-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10189970</ArticleId></ArticleIdList></Reference><Reference><Citation>Community Ment Health J. 2000 Jun;36(3):235-46</Citation><ArticleIdList><ArticleId IdType="pubmed">10933241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):418-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12519103</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2010 Jan 27;10:9</Citation><ArticleIdList><ArticleId IdType="pubmed">20105311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Jul;65(2):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11356233</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Nov 15;56(10):738-48</Citation><ArticleIdList><ArticleId IdType="pubmed">15556118</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1997 May;95(5):361-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9197898</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Sep;59(9):449-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9771814</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 1991 Mar;30(1):85-99</Citation><ArticleIdList><ArticleId IdType="pubmed">2044754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2008 Mar;23(2):95-105</Citation><ArticleIdList><ArticleId IdType="pubmed">18058849</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1984 Oct;52(5):873-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6501672</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Dec;157(12):2048-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11097977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1991 Aug;59(4):547-57</Citation><ArticleIdList><ArticleId IdType="pubmed">1918559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):361-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10847311</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2004 Aug 16;75(2):123-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15276217</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1990 Nov 21;264(19):2511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2232018</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2004 Nov;99(11):1382-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15500591</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hosp Pharm. 1982 Jan;39(1):101-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7055135</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2004 Mar;55(3):264-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15001726</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1990 Jan;18(1):17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">2136866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2004 Jun;192(6):395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">15167402</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Jul 15;36(2):124-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7948445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2001 Mar;7(2):109-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15990511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1991 Jan;21(1):15-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1827472</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Psychol. 2006 Dec;20(4):701-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17176206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Dec;6(6):504-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15541066</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Jul-Aug;44(4):293-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12923707</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementia (London). 2008;7(4):503-520</Citation><ArticleIdList><ArticleId IdType="pubmed">20228893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 May;63(5):384-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12019661</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Modif. 2008 May;32(3):267-301</Citation><ArticleIdList><ArticleId IdType="pubmed">18391049</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9585716</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):732-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18363424</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9435760</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Modif. 1990 Oct;14(4):457-89</Citation><ArticleIdList><ArticleId IdType="pubmed">2252468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Health Serv Res. 2002 Aug;29(3):288-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12216373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 1997 Jun;28(2):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9194011</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1995 Nov;46(11):1131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8564501</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 1993 Oct;16(10):1331-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8269790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1978 Oct;46(5):901-7</Citation><ArticleIdList><ArticleId IdType="pubmed">701569</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Jul 15;160(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18514326</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2006 Jan;44(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16300724</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 1997 Oct;92(10):1305-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9489047</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):904-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12963672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1998 Apr;49(4):531-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9550248</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Sep;147(9):1194-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1974746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Sep;42(9):887-96</Citation><ArticleIdList><ArticleId IdType="pubmed">2864032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Behav Med. 2003 Aug;26(1):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12867355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Jul;59(7):358-65</Citation><ArticleIdList><ArticleId IdType="pubmed">9714264</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):582-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11018229</ArticleId></ArticleIdList></Reference><Reference><Citation>Prev Med. 1994 Jul;23(4):481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7971876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Oct;66(10):1205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16259532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciba Found Symp. 1985;110:110-25</Citation><ArticleIdList><ArticleId IdType="pubmed">3845880</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2004 Nov-Dec;45(6):431-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15526253</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Drug Alcohol Abuse. 1991;17(4):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">1746501</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1994 Mar;89(3):975-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8124838</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2005 Mar;100(3):304-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15733244</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):415-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15826740</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2002 Mar;105(3):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11939969</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference><Reference><Citation>Eval Program Plann. 1979;2(3):197-207</Citation><ArticleIdList><ArticleId IdType="pubmed">10245370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 5:24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16225557</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Mar;71(3):296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">20331931</ArticleId></ArticleIdList></Reference><Reference><Citation>Eval Program Plann. 1983;6(3-4):299-313</Citation><ArticleIdList><ArticleId IdType="pubmed">10267258</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2000 Mar;20(2):191-206</Citation><ArticleIdList><ArticleId IdType="pubmed">10721497</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 2001 Summer;35(3):109-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12397882</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Feb;158:197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">1707323</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Aug 1;54(3):307-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12893106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12519101</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Quetiapine in bipolar disorder and cocaine dependence.</ArticleTitle><Pagination><MedlinePgn>406-11</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bipolar disorder is associated with the highest rates of substance abuse of any psychiatric illness. Therefore, treatments that stabilize mood and decrease drug use or cravings are of great interest. Atypical antipsychotics are in widespread use in patients with bipolar disorder. However, minimal data are available on their use in bipolar patients with comorbid substance abuse.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Open-label, add-on, quetiapine therapy was examined for 12 weeks in 17 outpatients with bipolar disorder and cocaine dependence. Subjects were evaluated with a structured clinical interview; Hamilton Depression Rating (HDRS), Young Mania Rating (YMRS), Brief Psychiatric Rating (BPRS) scales; and Cocaine Craving Questionnaire (CCQ). Urine samples and self-reported drug use were also obtained. Data were analyzed using a last observation carried forward method on all subjects given medication at baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant improvement from baseline to exit was observed in HDRS, YMRS, BPRS and CCQ scores (p &lt; or = 0.05). Dollars spent on cocaine and days/week of cocaine use decreased non-significantly, and urine drug screens did not change significantly from baseline to exit. Quetiapine was well tolerated, with no subjects to our knowledge discontinuing because of side-effects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of quetiapine was associated with substantial improvement in psychiatric symptoms and cocaine cravings. The findings are promising and suggest larger controlled trials of quetiapine are needed in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>E Sherwood</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas 75390, USA. sherwood.brown@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nejtek</LastName><ForeName>Vicki A</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>Perantie</LastName><ForeName>Dana C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Bobadilla</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019970" MajorTopicYN="N">Cocaine-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12519101</ArticleId><ArticleId IdType="pii">2o229</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2002.02229.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19816066</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-8638</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Neuro-Signals</Title><ISOAbbreviation>Neurosignals</ISOAbbreviation></Journal><ArticleTitle>Muscarinic receptors in psychiatric disorders - can we mimic 'health'?</ArticleTitle><Pagination><MedlinePgn>298-310</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000231896</ELocationID><Abstract><AbstractText>The concept that acetylcholine is involved in the pathophysiologies of psychiatric disorders has existed since the 1950s. There is very strong evidence implicating a dysfunctional muscarinic system in schizophrenia, +with less information available for bipolar disorder and major depressive disorder. The translation of this evidence into clinically viable treatments has been disappointing; hampered by problems associated with developing drugs that target the requisite members of the muscarinic family, rather than all of the receptors, which results in unacceptable side-effect profiles. The discovery of additional binding sites, other than the one occupied by acetylcholine, has revitalised research into this aspect of psychopharmacology. New compounds are now being developed that have the potential to selectively target individual muscarinic receptors in the central nervous system. The question that remains to be answered is whether stimulating central muscarinic receptors will result in the reestablishment of normal central muscarinic activity? The purpose of this review is to (i) summarise the data supporting a role of the muscarinic system in schizophrenia, bipolar disorder and major depressive disorder, and (ii) give an overview of some of the new selective muscarinic ligands that are currently in development and try to address the issue of re-establishing appropriate central muscarinic function.</AbstractText><CopyrightInformation>Copyright (c) 2009 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarr</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, The University of Melbourne, and Rebecca L. Cooper Research Laboratories, Mental Health Research Institute, Parkville, Vic., Australia. elscarr@unimelb.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurosignals</MedlineTA><NlmUniqueID>101134359</NlmUniqueID><ISSNLinking>1424-862X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>113</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19816066</ArticleId><ArticleId IdType="pii">000231896</ArticleId><ArticleId IdType="doi">10.1159/000231896</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17414683</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1527-4160</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Medication adherence and the use of long-acting antipsychotics in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>79-85</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adherence to treatment is a major determinant of outcome in bipolar disorder. Poor insight, attitudes towards treatment, and poor understanding of medications and the illness can all lead to reduced adherence. Nonadherence and partial adherence both also appear to play a significant role in relapse. Thirty to forty percent of patients with bipolar disorder who attempt to be adherent to treatment are actually only partially adherent. Clinicians frequently address the problem of poor adherence by adding an antipsychotic medication to the mood stabilizer regimen. The availability of a long-acting atypical antipsychotic raises the possibility of using this agent to prevent bipolar relapse.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The literature on the use of depot antipsychotics in bipolar illness is reviewed, based on a search of PubMed and Ovid Medline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No randomized, controlled trials of depot antipsychotics in bipolar illness have been performed. However, several case series and naturalistic trials that have used first generation agents suggest that depot antipsychotics are effective in reducing relapse in bipolar illness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Depot antipsychotics, including long-acting first and second generation agents, can be important adjuncts in the long-term management of bipolar illness. Controlled trials with these agents in bipolar disorder are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Mallakh</LastName><ForeName>Rif S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY 40202, USA. rselma01@louisville.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17414683</ArticleId><ArticleId IdType="doi">10.1097/01.pra.0000265764.87376.02</ArticleId><ArticleId IdType="pii">00131746-200703000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10804077</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mental health service use by elderly patients with bipolar disorder and unipolar major depression.</ArticleTitle><Pagination><MedlinePgn>160-6</MedlinePgn></Pagination><Abstract><AbstractText>Symptoms, functioning, and mental health service use were compared in older out-patients with bipolar disorder and unipolar depression. Bipolar outpatients (n = 37, mean age = 69.7) had higher total symptom severity and positive symptom scores, more impaired community-living skills, and earlier age at onset of illness than patients with unipolar depression (n = 85, mean age = 70.9). Bipolar elderly patients used almost four times the total amount of mental health services and were four times more likely to have had a psychiatric hospitalization over the previous 6 months. These findings underscore the need for effective services for elderly patients with bipolar disorder, who account for a minority of patients with affective disorders, but use a disproportionate amount of costly services.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>NH-Drtmouth Psychiatric Research Center, Lebanon 03766, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forester</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KO7-MHO1052</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009513" MajorTopicYN="N">New Hampshire</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014600" MajorTopicYN="N">Utilization Review</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10804077</ArticleId><ArticleId IdType="pii">S1064-7481(12)61474-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33858288</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>What impact does bipolar disorder staging have on the use of pharmacotherapy?</ArticleTitle><Pagination><MedlinePgn>1513-1516</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14656566.2021.1915988</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Jairo Vinícius</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande Do Sul, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Psychiatry, Hospital De Clínicas De Porto Alegre, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauer-Sant'Anna</LastName><ForeName>Márcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande Do Sul, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Psychiatry, Hospital De Clínicas De Porto Alegre, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>Lakshmi N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33858288</ArticleId><ArticleId IdType="doi">10.1080/14656566.2021.1915988</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12519099</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Thyroid function in mixed and pure manic episodes.</ArticleTitle><Pagination><MedlinePgn>393-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Associations of both overt thyroid disease as well as subclinical thyroid abnormalities with affective disorders have been well established. Similar associations have been reported with mixed mania and rapid cycling bipolar disorder. We tested for differences in overt and subclinical thyroid disease and subclinical differences in a large series of bipolar patients examined during mixed or pure manic episodes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Rates of previously diagnosed thyroid disease were compared by sex, race and manic subtype (mixed versus pure) in 443 patients. Serum thyroid stimulating hormone (TSH) and free thyroxine (FT4) concentrations obtained from patients with no clinical thyroid disease collected during manic and mixed bipolar episodes were compared using ANOVA statistics. Race was also included in the model and age was covaried.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rates of thyroid disease, in particular hypothyroidism, were higher in females and white people, and increased with advancing age. No differences were noted between subjects sampled during mixed or pure manic episodes. In patients with no history of thyroid disease, serum TSH and FT4 concentrations did not differ between manic subtypes or between sexes. TSH levels however, were significantly lower in African Americans.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We did not confirm past reports of associations of overt or subclinical thyroid disease with mixed manic episodes. African Americans had significantly lower serum TSH concentrations than white people, while FT4 levels did not differ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cassidy</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Duke-Umstead Bipolar Disorders Program, Duke University, Durham, NC, USA. cassi002@mc.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahearn</LastName><ForeName>E P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013960" MajorTopicYN="N">Thyroid Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12519099</ArticleId><ArticleId IdType="pii">1o214</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2002.01214.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26252722</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0795</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacopsychiatry</Title><ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine.</ArticleTitle><Pagination><MedlinePgn>211-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0035-1559635</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lamotrigine is licensed for treatment of epilepsy and prevention or at least delay of depressive episodes in bipolar disorder. The accepted therapeutic reference range (TRR) of lamotrigine for anticonvulsant treatment is 3 000-14 000 ng/ml. This TRR is often used for the therapy of bipolar disorders as well. This work presents serious doubts about this approach.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">KONBEST, a large TDM database containing patients' characteristics including diagnoses, doses, comedication and serum concentrations, was analyzed. Out of a total of 3 459 lamotrigine samples, 360 patients suffered from bipolar disorder. 82 of them benefitted from therapy with lamotrigine as judged by the clinical global impression of improvement (CGI-I) scale. Patients with a score of minimally (3), much (2) or very much improved (1) were considered as responders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The recommended lamotrigine maintenance dose for bipolar disorder is 200 mg/day; the doses prescribed in our samples ranged from 25 to 450 mg/day. Only 32 concentrations (39.0%) fitted into the TRR recommended for therapy of epilepsy; 50 (61.0%) did not reach it, none exceeded it. The lowest concentration was 177 ng/ml, the highest 11 871 ng/ml. A mean lamotrigine serum concentration of 3 341±2 563 ng/ml (̅x±SD) was detected in the patients who benefitted.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The authors conclude that in bipolar disorder lower lamotrigine serum concentrations lead to therapeutic benefit.</AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Unholzer</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinische Pharmakologie am Lehrstuhl mit Poliklinik für Psychiatrie und Psychotherapie und am Lehrstuhl für Pharmakologie und Toxikologie der Universität Regensburg/Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haen</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinische Pharmakologie am Lehrstuhl mit Poliklinik für Psychiatrie und Psychotherapie und am Lehrstuhl für Pharmakologie und Toxikologie der Universität Regensburg/Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatry</MedlineTA><NlmUniqueID>8402938</NlmUniqueID><ISSNLinking>0176-3679</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Pharmacopsychiatry. 2015 Nov;48(7):296</RefSource><PMID Version="1">26630654</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062313" MajorTopicYN="N">Databases, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="Y">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26252722</ArticleId><ArticleId IdType="doi">10.1055/s-0035-1559635</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6743720</PMID><DateCompleted><Year>1984</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>1984</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>High dose naloxone in depression.</ArticleTitle><Pagination><MedlinePgn>825-32</MedlinePgn></Pagination><Abstract><AbstractText>The behavioral effects of a 2 mg/kg iv bolus infusion of naloxone were compared with a placebo infusion using a double-blind design in a small group of inpatient depressives (n = 6) and normals (n = 8). Naloxone produced consistent and significant worsening in the rated signs and subjective symptoms of depression in the patients. In the normals, lesser changes in Hamilton depression and BPRS total scores were observed while none of the subjective scales were significantly altered. The data suggest that depressives manifest a more marked and subjectively more intense response to naloxone compared to normals. Further studies are required to confirm this preliminary finding and to clarify its relationship to the pathogenesis of depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Pickar</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sunderland</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>E A</ForeName><Initials>EA</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>36B82AMQ7N</RegistryNumber><NameOfSubstance UI="D009270">Naloxone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009270" MajorTopicYN="N">Naloxone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6743720</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8054405</PMID><DateCompleted><Year>1994</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>11</Issue><PubDate><Year>1994</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Disruption of circadian MHPG rhythmicity in major depression.</ArticleTitle><Pagination><MedlinePgn>830-42</MedlinePgn></Pagination><Abstract><AbstractText>Plasma concentrations of total (free plus conjugated) 3-methoxy-4-hydroxyphenylglycol (MHPG) were determined every 3 hr for a 24-hr period in 32 unipolar depressed patients, 11 bipolar depressed patients, and 12 healthy subjects. Each subject's circadian MHPG rhythmicity was modeled by a sinusoidal function. Temporal parameters were estimated by linear least squares regression with a fixed 24-hr period. The variabilities associated with estimates of circadian amplitude and acrophase were roughly twice as large in the patients compared to healthy subjects. Phase advances were associated most significantly with the agitated rather than the retarded subtype of depression, and with first episode depressions. Treatment with desipramine (n = 26) did not alter significantly any of the model parameters and had no effect on circadian variability in any patient group. The data overall support a dysregulation theory for depressive illness with phase advances representing one manifestation of such dysregulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piletz</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson 39216-4505.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMet</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gwirtsman</LastName><ForeName>H E</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Halaris</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIMH MH-33109</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIMH MH-37664</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>534-82-7</RegistryNumber><NameOfSubstance UI="D008734">Methoxyhydroxyphenylglycol</NameOfSubstance></Chemical><Chemical><RegistryNumber>TG537D343B</RegistryNumber><NameOfSubstance UI="D003891">Desipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008734" MajorTopicYN="N">Methoxyhydroxyphenylglycol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8054405</ArticleId><ArticleId IdType="pii">0006-3223(94)90018-3</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(94)90018-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18087202</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0348</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>1</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Psychotherapy and psychosomatics</Title><ISOAbbreviation>Psychother Psychosom</ISOAbbreviation></Journal><ArticleTitle>Gaps and limitations of psychological interventions for bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>4-11</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To highlight gaps or limitations in applying evidence-based psychological therapies as an adjunct to medication in the management of bipolar disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">General and specific gaps in knowledge or perceived limitations were determined by the authors and published examples were identified illustrating these potential barriers to the use or application of adjunctive therapies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Research on the benefits of psychological therapies in bipolar disorders has progressed dramatically in the last decade. There are some uncertainties that need to be further investigated. These can be broadly classified as: for whom should therapy be provided, what therapy and when should therapy be commenced. The latter can be seen from the perspective of both current mental state as well as length of history and number of recurrences. Other issues frequently highlighted by researchers in the field relate to mediators and moderators of therapy effects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Gaps in our knowledge about therapy for bipolar disorder mirror those that exist whenever new treatments, including medications, are introduced into routine clinical practice. Many of these key questions relate to differences between efficacy and effectiveness of adjunctive therapies, the long-term durability of any benefits and mechanisms by which therapies achieve their effects. These can be explored using currently existing scientific paradigms.</AbstractText><CopyrightInformation>2008 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, UK. j.scott@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychother Psychosom</MedlineTA><NlmUniqueID>0024046</NlmUniqueID><ISSNLinking>0033-3190</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019348" MajorTopicYN="N">Empiricism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18087202</ArticleId><ArticleId IdType="pii">000110054</ArticleId><ArticleId IdType="doi">10.1159/000110054</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16815557</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>1-2</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Distinguishing bipolar and unipolar disorders: an isomer model.</ArticleTitle><Pagination><MedlinePgn>67-73</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As division between unipolar and bipolar disorders can be problematic, we sought to develop a self-report questionnaire of mood 'highs' that would both distinguish true Bipolar Disorder from any elevated mood states in unipolar depression and sharpen the distinction between Bipolar I and II conditions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A 46-item questionnaire was developed and completed by 157 out-patients presenting with a major depressive episode, and clinically diagnosed as having either Bipolar I (BP-I), Bipolar II (BP-II) or Unipolar (UP) depression, although DSM-IV duration criteria for BP-I and BP-II were not imposed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Factor analyses identified four key constructs to mood 'highs', while additional analyses refined the questionnaire to 27 items. The refined measure was highly accurate in distinguishing composite Bipolar (BP-I and BP-II) from UP subjects (AUC = 0.93, sensitivity = 81%; specificity = 98%, positive predictive value = 0.95). Questionnaire scores were similar for BP-I and BP-II subjects, raising the possibility that the core mood state differs little in severity across the two expressions, and that their distinction allows an alternative model that weights the presence or absence of psychotic features.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study advances understanding of boundary distinctions between bipolar and unipolar mood disorders, and between BP-I and BP-II conditions, and allows consideration of a model distinguishing BP-I from BP-II by the presence of psychotic features only. The described model is the mirror image of a hierarchical structural model for conceptualizing psychotic and melancholic depression, allowing an 'isomer model' for linking the mood swing states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, and Black Dog Institute, Prince of Wales Hospital, Randwick 2031, Sydney, Australia. g.parker@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>Dusan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tully</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16815557</ArticleId><ArticleId IdType="pii">S0165-0327(06)00246-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.05.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1633434</PMID><DateCompleted><Year>1992</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-977X</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>1992</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Adding lithium to antidepressant therapy: factors related to therapeutic potentiation.</ArticleTitle><Pagination><MedlinePgn>161-5</MedlinePgn></Pagination><Abstract><AbstractText>Lithium augmentation of antidepressant drugs was studied in 51 patients with endogenous refractory depression. The remission after 28 days of lithium was obtained in 28 patients (55%). Better effect of lithium was shown in bipolar than unipolar patients, with subjects with lower pre-lithium severity of depression and in those with rapid improvement (within 7 days) on lithium addition. Factors such as age, gender, number of prior antidepressant (or ECT) treatments, type of preceding antidepressant, mean plasma lithium concentration and the results of DST did not show any association with the outcome of lithium augmentation. The 'priming' effect of lithium may contribute to the mechanism of lithium potentiation in a proportion of depressed patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical Academy, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matkowski</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1633434</ArticleId><ArticleId IdType="pii">0924-977X(92)90027-6</ArticleId><ArticleId IdType="doi">10.1016/0924-977x(92)90027-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19592383</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1095-158X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Psychiatric rehabilitation journal</Title><ISOAbbreviation>Psychiatr Rehabil J</ISOAbbreviation></Journal><ArticleTitle>The impetus of recovery.</ArticleTitle><Pagination><MedlinePgn>60-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2975/33.1.2009.60.61</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Keysha M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Rochester Psychiatric Center, Rochester, NY 14620, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Rehabil J</MedlineTA><NlmUniqueID>9601800</NlmUniqueID><ISSNLinking>1095-158X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001325" MajorTopicYN="N">Autobiographies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004493" MajorTopicYN="N">Education</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006703" MajorTopicYN="N">Homeless Persons</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012050" MajorTopicYN="N">Rehabilitation, Vocational</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015406" MajorTopicYN="N">Single Parent</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19592383</ArticleId><ArticleId IdType="pii">L26V007754670672</ArticleId><ArticleId IdType="doi">10.2975/33.1.2009.60.61</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6709350</PMID><DateCompleted><Year>1984</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-6002</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>15</Issue><PubDate><Year>1984</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Orvosi hetilap</Title><ISOAbbreviation>Orv Hetil</ISOAbbreviation></Journal><ArticleTitle>[Kidney function tests during preventive lithium therapy].</ArticleTitle><Pagination><MedlinePgn>883-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipcsey</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Klement</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fekete</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Vesemuködés vizsgálatok lítium profilaxisban.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Orv Hetil</MedlineTA><NlmUniqueID>0376412</NlmUniqueID><ISSNLinking>0030-6002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>4</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>4</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6709350</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23588581</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1102</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of women's mental health</Title><ISOAbbreviation>Arch Womens Ment Health</ISOAbbreviation></Journal><ArticleTitle>Gender differences in health-related quality of life in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>317-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00737-013-0351-1</ELocationID><Abstract><AbstractText>Health-related quality of life (HRQOL) is a widely accepted measure of illness state that is related to morbidity and mortality. Findings from various populations show that women report lower HRQOL than men. We analyzed baseline HRQOL data for gender differences from a multisite, randomized controlled study for adults with bipolar disorder. HRQOL was assessed using the 12-item Short Form (SF-12) physical component summary (PCS) and mental component summary (MCS) health scales. Multivariate linear and bivariate regression models examined differences in self-reported data on demographics, depressive symptoms (nine-item Patient Health Questionnaire), bipolar disorder symptoms (Internal State Scale), and medical comorbidities. Out of 384 enrolled (mean age = 42 years), 256 were women (66.7 %). After controlling for sociodemographic characteristics and clinical factors, women had lower SF-12 PCS scores than men [β = -1.78, standard error (SE) = 0.87, p &lt; 0.05], indicating worse physical health, but there were no gender differences in MCS scores. After controlling for patient factors including medical and behavioral comorbidities, the association between gender and PCS score was no longer significant. Of the medical comorbidities, pain was associated with lower PCS scores (β = -4.90, SE = 0.86, p &lt; 0.0001). Worse physical HRQOL experienced by women with bipolar disorder may be explained by medical comorbidity, particularly pain, suggesting the importance of gender-tailored interventions addressing physical health conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de la Cruz</LastName><ForeName>Maria Syl D</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Family and Community Medicine, Thomas Jefferson University, 833 Chestnut St., Suite 301, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Zongshan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Goodrich</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH079994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R301MH79994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Arch Womens Ment Health</MedlineTA><NlmUniqueID>9815663</NlmUniqueID><ISSNLinking>1434-1816</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23588581</ArticleId><ArticleId IdType="doi">10.1007/s00737-013-0351-1</ArticleId><ArticleId IdType="pmc">PMC3722292</ArticleId><ArticleId IdType="mid">NIHMS468391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med Care. 1996 Mar;34(3):220-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8628042</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2009 Oct;71(8):894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">19661187</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2008 Jun;59(6):663-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18511587</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2008;22(5):389-406</Citation><ArticleIdList><ArticleId IdType="pubmed">18399708</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2005 Nov 15;3:72</Citation><ArticleIdList><ArticleId IdType="pubmed">16288650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Sep;125(1-3):35-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20570367</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1985;317:1-34</Citation><ArticleIdList><ArticleId IdType="pubmed">3861072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1996 Nov;101(5):526-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8948277</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2000 May;101(5):374-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10823297</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2006 Nov;63(9):2367-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16884840</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2003;21(9):601-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12807364</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2006 Jan 24;4:5</Citation><ArticleIdList><ArticleId IdType="pubmed">16433917</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2002 Jan;37(1):31-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11924747</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2006 Dec 01;4:91</Citation><ArticleIdList><ArticleId IdType="pubmed">17140436</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1998 Sep 14;158(16):1789-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9738608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Dec;2(4):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11252648</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Jun;49(3):189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9629948</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20888048</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2005 Mar;14(2):479-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15892437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">12519100</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jun;167(6):708-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20231325</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 Feb;60(2):147-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1993;29(2):321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8290681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):366-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2005 Jan;53(1):108-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15667386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 May;86(1):47-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15820270</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12063148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">14525556</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 Nov-Dec;46(6):405-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16275207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1993 Apr 15;118(8):622-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8452328</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Jan-Mar;57(1-3):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10708837</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2001 Sep;16(9):606-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22854584</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2012</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1989-4600</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><MedlineDate>2012 Apr-Jun</MedlineDate></PubDate></JournalIssue><Title>Revista de psiquiatria y salud mental</Title><ISOAbbreviation>Rev Psiquiatr Salud Ment</ISOAbbreviation></Journal><ArticleTitle>Neuronal migration, apoptosis and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>127-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rpsm.2011.11.005</ELocationID><Abstract><AbstractText>Bipolar disorder, like the majority of psychiatric disorders, is considered a neurodevelopment disease of neurodevelopment. There is an increased rate of neuronal birth and death during this development period. In the particular case of the processes that determine neuronal death, it is known that those neurons that establish connections have to be removed from the central nervous system. There is a deficit of GABAergic interneurons in the cerebral cortex in bipolar disorder, accompanied by overexpression of proapoptic genes. There is also an alteration in the expression of molecules that mediate in the migration of these neurons and their inclusion in functional synapsis during the foetal stage. The role of these molecules in the neuronal death pathways by apoptosis will be reviewed here in an attempt to establish biological hypotheses of the genesis of bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2011 SEP y SEPB. Published by Elsevier Espana. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uribe</LastName><ForeName>Ezequiel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universidad de Carabobo, Escuela de Medicina, Departamento de Fisiología, Laboratorio de Neurofisiología, Valencia, Venezuela. ezequiel.uribe@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wix</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Psiquiatr Salud Ment</MedlineTA><NlmUniqueID>101528851</NlmUniqueID><ISSNLinking>1888-9891</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="Y">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22854584</ArticleId><ArticleId IdType="pii">S1888-9891(11)00182-0</ArticleId><ArticleId IdType="doi">10.1016/j.rpsm.2011.11.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18391127</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2008</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence.</ArticleTitle><Pagination><MedlinePgn>386-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archpsyc.65.4.386</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Both bipolar disorder type I and type II are characterized by frequent affective episode relapse and/or recurrence. An increasingly important goal of therapy is reducing chronicity by preventing or delaying additional episodes.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether the continued presence of subsyndromal residual symptoms during recovery from major affective episodes in bipolar disorder is associated with significantly faster episode recurrence than asymptomatic recovery and whether this is the strongest correlate of early episode recurrence among 13 variables examined.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">An ongoing prospective, naturalistic, and systematic 20-year follow-up investigation of mood disorders: the National Institute of Mental Health Collaborative Depression Study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Five academic tertiary care centers.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Two hundred twenty-three participants with bipolar disorder (type I or II) were followed up prospectively for a median of 17 years (mean, 14.1 [SD, 6.2] years).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Participants defined as recovered by Research Diagnostic Criteria from their index major depressive episode and/or mania were divided into residual vs asymptomatic recovery groups and were compared according to the time to their next major affective episodes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants recovering with residual affective symptoms experienced subsequent major affective episodes more than 3 times faster than asymptomatic recoverers (hazard ratio, 3.36; 95% confidence interval, 2.25-4.98; P &lt; .001). Recovery status was the strongest correlate of time to episode recurrence (P &lt; .001), followed by a history of 3 or more affective episodes before intake (P = .007). No other variable examined was significantly associated with time to recurrence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In bipolar disorder, residual symptoms after resolution of a major affective episode indicate that the individual is at significant risk for a rapid relapse and/or recurrence, suggesting that the illness is still active. Stable recovery in bipolar disorder is achieved only when asymptomatic status is achieved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Judd</LastName><ForeName>Lewis L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California-San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0603, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schettler</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Coryell</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Maser</LastName><ForeName>Jack D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="Y">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="Y">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="Y">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="Y">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391127</ArticleId><ArticleId IdType="pii">65/4/386</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.65.4.386</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28867391</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><PubDate><Year>2018</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts.</ArticleTitle><Pagination><MedlinePgn>372-383</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(17)30474-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2017.08.024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is evidence that major depression (MDD) and bipolar disorder (BD) are accompanied by activated immune &amp; oxidative (I&amp;O) pathways.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To compare I&amp;O biomarkers between MDD and BD we assessed serum levels of thiobarbituric acid reactive substances (TBARS; a lipid peroxidation marker), soluble interleukin-2 receptor (sIL-2R), sIL-6R, IL-α, sIL-1R antagonist (sIL-1RA), tumor necrosis factor receptor 60kDa/80kDa (sTNFR60/R80) in 114 MDD and 133 BD patients, and 50 healthy controls. We computed z-unit weighted indices reflecting the 5 cytokine receptor levels (zCytR), cell-mediated immunity (zCMI) and I&amp;O pathways (zCMI+TBARS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There are no significant differences in biomarkers between MDD and BD. BD/MDD with atypical features is characterized by increased sIL-6R and TBARS, whereas melancholia is associated with higher TBARS and lower sTNFR60 levels. Severity of illness, as measured with the Hamilton Depression Rating Scale, is correlated with increased sIL-6R, sTNFR80, TBARS, zCytR and zCMI+TBARS. The number of episodes the year prior to blood sampling is positively associated with sTNFR80, TBARS, zCMI, zCMI+TBARS, while number of hospitalizations is positively associated with sIL-1RA. Prior suicidal attempts are associated with increased sIL-1RA, IL-1α, zCMI, TBARS and zCMI+TBARS, while TBARS is associated with current suicidal ideation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are no I&amp;O biomarker differences between MDD and BD. Atypical depression is associated with increased IL-6 trans-signaling and lipid peroxidation. Severity of depression, number of episodes and suicidal attempts are associated with activated I&amp;O pathways. Increased TBARS is the single best predictor of BD/MDD, atypical depression, melancholia and current suicidal ideation.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sowa-Kućma</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, Polish Academy of Sciences, Laboratory of Trace Elements Neurobiology, Department of Neurobiology, Smetna Street 12, 31-343 Krakow, Poland; Department of Human Physiology, Institute of Clinical and Experimental Medicine, Medical Faculty, University of Rzeszow, Al. Kopisto Street 2a, 35-959 Rzeszów, Poland. Electronic address: sowa@if-pan.krakow.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Styczeń</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siwek</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misztak</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, Polish Academy of Sciences, Laboratory of Trace Elements Neurobiology, Department of Neurobiology, Smetna Street 12, 31-343 Krakow, Poland; Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Rafał J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Drug Management, Jagiellonian University Medical College, Grzegórzecka 20, 31-531 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudek</LastName><ForeName>Dominika</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznań University of Medical Sciences, Szpitalna 27/33, 60-572 Poznań, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, Polish Academy of Sciences, Laboratory of Trace Elements Neurobiology, Department of Neurobiology, Smetna Street 12, 31-343 Krakow, Poland; Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland. Electronic address: nowak@if-pan.krakow.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; IMPACT Strategic Research Centre, Deakin University, School of Medicine and Barwon Health, Geelong, VIC, Australia; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria; Revitalis, Waalre, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="N">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017392" MajorTopicYN="N">Thiobarbituric Acid Reactive Substances</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Immune</Keyword><Keyword MajorTopicYN="N">Major depression</Keyword><Keyword MajorTopicYN="N">Melancholia</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28867391</ArticleId><ArticleId IdType="pii">S0278-5846(17)30474-8</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2017.08.024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15107653</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0268-1315</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>International clinical psychopharmacology</Title><ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>A review of acute treatments for bipolar depression.</ArticleTitle><Pagination><MedlinePgn>113-24</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar patients generally spend much more time in the depressed phase of their illness than the manic phase, and there are many more bipolar type II and bipolar spectrum disorder patients than there are bipolar type I. Additionally, there is a significant risk of suicide in bipolar patients when depressed. The treatment of the depressed phase of bipolar disorder is therefore a matter of some priority. Here, we review current evidence supporting the use of five groups of treatments: anti-depressants; lithium; anti-convulsants (valproate, and carbamazepine, lamotrigine, gabapentin); anti-psychotics; and other treatments (electroconvulsive therapy, benzodiazepines, sleep-deprivation, and dopamine agonists). From this review, it is apparent that the literature regarding the treatment of bipolar depression is significantly limited in several key areas. Nonetheless, from the evidence currently available, the treatments with the best evidence for efficacy are selective serotonin reuptake inhibitors (SSRIs) and lamotrigine. There is also some evidence in favour of bupropion and moclobemide. Although lithium and olanzapine monotherapies can also be beneficial, they appear less efficacious than antidepressants. One of the major concerns about treatment with antidepressants has been the risk of precipitating a switch into mania. However, recent studies suggest that, if a mood stabilizer and antidepressant are given concurrently, then the risk of switching is minimized. There is also recent evidence for an independent antidepressant action for at least one atypical antipsychotic. Therefore, the conclusion from this review, in contrast to previous suggestions, is that a combination of an atypical antipsychotic and either an SSRI or lamotrigine may provide a useful first-line treatment for depressed bipolar disorder patients. Further research is clearly required to examine this approach and compare it with other possible treatment options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silverstone</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neuroscience, University of Alberta, Edmonton, Alberta, Canada. peter.silverstone@ualberta.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverstone</LastName><ForeName>Trevor</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Clin Psychopharmacol</MedlineTA><NlmUniqueID>8609061</NlmUniqueID><ISSNLinking>0268-1315</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>205</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15107653</ArticleId><ArticleId IdType="pii">00004850-200405000-00001</ArticleId><ArticleId IdType="doi">10.1097/00004850-200405000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29882276</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>336-347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12915</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Bipolar disorder is associated with impairments in social cognition including the recognition of happy faces. This is accompanied by imbalanced cortico-limbic response to emotional faces. We found that EPO improved the recognition of happy faces in patients with bipolar disorder. This randomized, controlled, longitudinal fMRI study explores the neuronal underpinnings of this effect.</AbstractText><AbstractText Label="METHOD">Forty-four patients with bipolar disorder in full or partial remission were randomized to eight weekly erythropoietin (EPO; 40 000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Participants underwent whole-brain fMRI at 3T, mood ratings and blood tests at baseline and week 14. During fMRI, participants viewed happy and fearful faces and performed a gender discrimination task.</AbstractText><AbstractText Label="RESULTS">Thirty-four patients had complete pre- and post-treatment fMRI data (EPO: N = 18, saline: N = 16). Erythropoietin vs. saline increased right superior frontal response to happy vs. fearful faces. This correlated with improved happiness recognition in the EPO group. Erythropoietin also enhanced gender discrimination accuracy for happy faces. These effects were not influenced by medication, mood, red blood cells or blood pressure.</AbstractText><AbstractText Label="CONCLUSIONS">Together with previous findings, the present observation suggests that increased dorsal prefrontal attention control is a common mechanism of EPO-associated improvements across several cognitive domains.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>K W</ForeName><Initials>KW</Initials><Identifier Source="ORCID">0000-0003-2572-1384</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>N A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmer</LastName><ForeName>C J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrenreich</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0001-9377-9436</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5982-1335</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macoveanu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siebner</LastName><ForeName>H R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Det Frie Forskningsråd</Agency><Country>International</Country></Grant><Grant><Agency>Savvaerksejer Juhl's Mindefond</Agency><Country>International</Country></Grant><Grant><Agency>Beckett Fonden</Agency><Country>International</Country></Grant><Grant><Agency>Novo Nordisk Foundation</Agency><Country>International</Country></Grant><Grant><GrantID>R59 A5399</GrantID><Agency>Lundbeck Foundation</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11096-26-7</RegistryNumber><NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004921" MajorTopicYN="N">Erythropoietin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066499" MajorTopicYN="N">Facial Recognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006240" MajorTopicYN="Y">Happiness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="Y">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012938" MajorTopicYN="Y">Social Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">neurocognition</Keyword><Keyword MajorTopicYN="Y">neuroimaging</Keyword><Keyword MajorTopicYN="Y">randomized controlled trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29882276</ArticleId><ArticleId IdType="doi">10.1111/acps.12915</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4019429</PMID><DateCompleted><Year>1985</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>8</Issue><PubDate><Year>1985</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>L-phenylalanine.</ArticleTitle><Pagination><MedlinePgn>355</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simonson</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>KV2JZ1BI6Z</RegistryNumber><NameOfSubstance UI="D011736">Pyridoxine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011736" MajorTopicYN="N">Pyridoxine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4019429</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2813609</PMID><DateCompleted><Year>1989</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>8</Issue><PubDate><Year>1989</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[Results of the use of lithium to prevent recurrence of affective psychosis].</ArticleTitle><Pagination><MedlinePgn>476-84</MedlinePgn></Pagination><Abstract><AbstractText>The efficacy of lithium treatment in preventing relapse in phasal psychoses was tested by the re-examination of 99 patients at a Dresden clinic whose treatment had on average exceeded ten years. Results and progress were compared with those of patients starting treatment since the introduction of the lithium treatment in the year 1979. Phase or subphase frequency and duration, conditions of treatment, suicide attempts, unfitness for work, and registration as a disabled person were among the aspects considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Neurologie der Medizinischen, Akademie Carl Gustav Carus, Dresden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heisig</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Felber</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>König</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ergebnisse der Lithium-Rezidivprophylaxe affektiver Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2813609</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>